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ABSTRACT OF DISSERTATION 
 
THE ROLE OF APOB-CONTAINING LIPOPROTEINS IN ABDOMINAL AORTIC 
ANEURYSM 
 
Abdominal aortic aneurysm (AAA) is a devastating disease that exhibits 
permanent lumen expansion typically in the infrarenal aorta. AAA is prevalent 
among aged population, especially in males. Despite the incidence in women is 
lower, studies indicate the tortuosity is more severe and aortic rupture risk is 
higher in women. In most patients, AAA remains asymptomatic until it ruptures 
leading to sudden and fatal hemorrhage.  
 
To date, there is no proven medical therapy that can prevent the expansion or 
rupture. Human observational studies implicate the presence of AAA is 
associated with both high plasma low-density lipoprotein-cholesterol (HDL-C) 
and low plasma high-density lipoprotein-cholesterol (HDL-C) concentrations. To 
examine the role of specific lipoproteins in development of AAA, angiotensin 
(Ang) II-induced AAA was firstly determined in apolipoprotein AI deficient (apoAI 
-/-) mice in both C57BL/6 and LDL receptor deficient (LDL receptor -/-) 
backgrounds. The deletion of apoAI led to a significant decrease of HDL-C 
concentrations. However, we were unable to define any exacerbation of AngII-
induced AAA in either normo- or hyperlipidemic mice with apoAI deficiency. Next 
we compared AngII-induced AAA formation using multiple mouse strains with 
dietary manipulation to generate different severities of hypercholesterolemia. We 
demonstrated the apolipoprotein B (apoB)-containing lipoproteins promoted the 
development of AngII-induced AAA. Moreover, ezetimibe administration 
significantly reduced both apoB-containing lipoproteins and AAA formation. 
Together, our studies demonstrate that elevated apoB-containing lipoproteins, 
contribute to the development of AngII-induced AAA. 
 
To investigate the role of apoB-containing lipoproteins on established AAA, male 
LDL receptors -/- mice fed a Western diet were infused with AngII for 4 weeks to 
induced AAA. Then mice with AAA were stratified into either a group maintained 
on western diet or switched to a normal diet. AngII infusion was continued for an 
additional 8 weeks. The diet switch resulted in significantly reduced plasma 
cholesterol concentrations, which was attributable to the decrease of apoB-
containing lipoproteins. We found a profound inhibition of aneurysm progression 
in diet switched mice associated with attenuated macrophage accumulation and 
medial thickening. Collectively, our data demonstrate that apoB-containing 
lipoproteins promote the progression of established AAA.  
KEYWORDS: Abdominal Aortic Aneurysm, Angiotensin II, ApoAI, ApoB-
containing Lipoproteins, established aneurysm 
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1 
Chapter one: Introduction 
This chapter is based on a review published in “Curr Pharm 
Des. 2015;21(28):4035-48” with Jing Liu as the first author.  
1.1 Human Abdominal Aortic Aneurysm 
1.1.1 Epidemiology of Human AAA  
Human abdominal aortic aneurysm (AAA) is the most common aneurysm of 
large arteries and it constitutes more than 60% of all cases. It most commonly 
occurs in the infrarenal aorta. The abdominal aorta is considered aneurysmal if 
it is at least 1.5 times the normal aortic diameter (1). The overall prevalence of 
AAA in developed countries is approximately 5%. The disease is more common 
in males, with a 4 times greater incidence than in women; while women afflicted 
with AAA have more severe tortuosity and a worse prognosis. During the 20th 
century, many developed countries have reported a consistent increase of 
incidence and mortality associated with AAA (2-6). Aortic aneurysms contribute 
to the 13th leading cause of death in the United States due to the fatal rupture. 
AAA mortality is greatest among those previously undiagnosed who present 
with rupture. These individuals have up to 90% mortality rate if rupture occurs 
outside the hospital (7-11). Even those undergoing surgical repair, only 50% of 
patients will survive beyond 30 days (12). 
Given the adverse epidemiological trends, attempts have been made to 
improve the incidence of AAA in the past two decades. Recently, systematic 
evaluation of the global epidemiology of AAA has shown the decline of the 
disease burden. The age-specific prevalence rate per 100,000 ranged from 
8.43 (40-44 years age group) to 2,422.53 (75-95 year age group) in 1990; while 
the corresponding range in 2010 was 7.88 to 2, 2274.82. Although the 
incidence and prevalence were higher in developed countries than developing 
countries, the rate within each stratum has decreased in the past two decades. 
Of note, the regional assessment reveals certain countries had a most 
appreciable improvement while others had increased incidence and 
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prevalence, which highlights the need for further surveillance efforts and 
intervention in these countries (13).  
1.1.2 Risk Factors for Human AAAs  
1.1.2.1 Risk factors associated with AAA development  
Most patients with AAA are absent of clinical symptoms until AAA rupture that 
leads to sudden and fatal hemorrhage. The evaluation of risk factors is helpful 
in determining the risk of developing AAA, facilitating the early diagnosis and 
improving the prognosis. The identified risk factors include advanced age, male 
gender, smoking, family history and dyslipidemia. A number of factors such as 
coronary artery disease, atherosclerosis, hypertension, and ethnicity have also 
been identified as predisposing factors for AAA development. 
 
Age Mean aortic diameter increases with age in both men and women (14). 
Clinically relevant aneurysms (at least 4 cm in diameter) are found in about 1 
percent of men 55 to 64 years of age, and the prevalence increases by 2 to 4 
percent per decade thereafter (13-16).  
 
Gender Although women have a higher risk of rupture and worse prognosis, 
the prevalence of AAA is 4 times higher in men. Women less than 55 years of 
age rarely present with aneurysms. In addition, the age-related increase in men 
is more pronounced than that in women.  
 
Smoking Smoking is one of the strongest risk factors that is independently 
associated with presence of human AAA. Current smokers were 7.6 times more 
likely to have an AAA while ex-smokers were 3 times more likely to have an 
AAA compared with the non-smokers (17). The association is closely related to 
the number of years of smoking and inversely related with the years of smoking 
cessation (18). The risk of AAA increases by 4% each year in smokers, while 
smoking cessation slowly decline in the risk of the AAA occurrence, 
approximately 1/30 of the original risk per year of smoking cessation (15, 17). 
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Family history Family history is another potential risk factor that has 
significantly increases the prevalence of AAA. The risk of AAA may increase 4 
fold in a patient with a first-degree relative undergoing surgical intervention for 
an AAA (19). 
1.1.2.2 Risk factor associated with AAA rupture  
Rupture of AAA is a devastating event that occurs during progression of the 
disease. Many patients succumb pre or post-surgical repair, and many may not  
even reach the hospital. Only a few patients will survive after the surgery repair. 
The likelihood that an aneurysm will rupture is profoundly influenced by various 
factors including aneurysm size, expansion rate, current smoking status and 
gender (20). Other risk factors such as uncontrolled hypertension, shape, and 
intramural thrombus formation have also been reported which cause 
mechanical stress and hypoxia. These effects significantly increase the burden 
of the weakened AAA wall (21).  
 
Aneurysm size Aneurysm size is the most robust predictor of the likelihood of 
rupture. The risk of rupture increases exponentially with elevated aneurysm 
diameter. Based on studies of the natural history of aneurysms prior to the 
elective repair, the estimated annual rupture risk according to AAA diameter is 
listed below (22, 23): 
 
<4.0 in diameter                 - 0% 
4.0 cm-4.9 cm in diameter - 0.5-5% 
5.0 cm-5.9 cm in diameter - 3-15% 
6.0 cm-6.9 cm in diameter - 10-20% 
7.0 cm–7.9 cm in diameter - 20-40% 
≥8.0 cm in diameter            - 30-50% 
 
Importantly, the initial size of the aneurysms when first detected has been 
shown as an independent risk factor for rupture. In the UK Small Aneurysm 
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Trial, patients that had AAA rupture had larger mean initial abdominal aortic 
diameters compared to ones without rupture. The baseline diameter of AAA 
has also been associated with the expansion rate of AAA, which is an 
independent risk factor for AAA rupture (24). Every 10 mm larger diameter 
increment detected at baseline led to an additional 1.29 mm expansion.  
 
Expansion rate Expansion rate is an important determinant in monitoring the 
risk of rupture (25, 26). Evidence indicates aneurysms with 0.5 cm expansion or 
more over a six month follow-up are more prone to rupture (27). Moreover, 
patients with ruptured AAA had over double the rate of expansion compared 
with individuals with non-ruptured AAA (28).   
 
Smoking Smokers are at a great risk of a large spectrum of cardiovascular 
diseases. It has been consistently reported that smoking is not only a risk factor 
for the initiation of AAA, but also significantly contributes to the aneurysm 
expansion and rupture (21, 29). Current smoking has been shown to alter other 
independent risk factors that are associated with AAA rupture such as higher 
mean blood pressure and poor lung function (30, 31). Of note, only one 
manuscript reported that current smokers had a borderline significant increase 
of AAA rupture, which may indicate the inaccuracy of self-reporting of smoking 
status (20). Only after plasma cotinine (a long-lived metabolite of nicotine) was 
measured and used as the index of smoking, was the significant contribution of 
current smoking detected. 
 
Sex Despite the prevalence of AAA being 4 times higher in men, evidence 
clearly indicates a 3 to 4-fold increased risk of rupture in women. The mean 
AAA diameter predisposed to rupture in women is 5 cm while the 
corresponding size in men is 6 cm (20, 32, 33). One possible explanation for 
the higher risk of rupture may be the smaller diameter of the normal aorta in 
women; male aortas are larger than their female counterparts. Currently, 
patients identified with small aneurysm (3.0-5.4 cm) are under regular 
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ultrasound surveillance. Those reaching the selected threshold (5.5 cm) are 
referred for aneurysm repair by open surgery or endovascular repair (33). 
Given the gender-specific baseline of aortic diameter and more compliant 
aortas in women, a lower intervention threshold for women has been suggested 
instead of this rigid criteria (22). The adjustment of the AAA diameter for body 
surface area and the ratio of infrarenal/suprarenal diameter also have been 
shown to be a better predictor of AAA rupture risk in women (34, 35). 
1.1.3 Management of Human AAAs  
The rupture of the asymptomatic AAA is the major consideration for this 
disease. Only 10 to 15 percent of patients survive a ruptured AAA.  Of the 
patients reaching the hospital alive, only half will survive the emergency 
surgical repair (20). Although a few patients with AAA die from ruptured 
aneurysm, other cardiovascular diseases threaten their lives (36). The 
management options for AAA patients include screening and surveillance, risk 
factor reduction, medical therapy, surgery and endovascular stenting.  
 
The one-time ultrasound screening has been recommended for all men over 
the age of 65, or 55 for those with a family history of AAA. Women over the age 
of 65 who have smoked, or have a family history should also have ultrasound 
screening. If a AAA is detected during screening, follow-up intervals are 
recommended: 5 years for patients with an AAA diameter between 2.6-2.9 cm; 
3 years for patients with an AAA of 3.0-3.4 cm; 12 months for patients with an 
AAA diameter of 3.5-4.4 cm; and 6 months for patients with an AAA diameter of 
4.4-5.4 cm (36).   
 
Smoking has been shown consistently as the major contributor to aneurysm 
growth and rupture. Smoking increases the growth rate by 20 to 25 percent, 
which accelerates the risk of rupture for AAA patients (17, 24, 31, 37, 38). Data 
from 1743 patients demonstrated a more profound expansion (mean of 0.29 cm 
per year) in current smokers than in former smokers (mean of 0.25 cm per 
year) (15). The risk of rupture and rupture-related death are higher in current 
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smokers than former and non-smokers (20, 39). Therefore, the ACC/AHA 
guidelines recommend that smoking cessation should be advocated to all 
individuals with AAA or a positive family history of AAA (27).  
 
Patients with AAA have markedly increased cardiovascular disease risks, which 
in turn worsen prognosis of this disease. During the surveillance period, the 
therapeutic goal is to prevent aneurysm from reaching a size with a high risk of 
rupture. Patients are encouraged to seek appropriate management for other 
risk factors such as hypertension, hypercholesterolemia, diabetes and 
atherosclerosis. Insufficient evidence supports the protective effects of 
doxycycline or roxithromycin in reducing AAA growth (36). Statins and 
angiotensin-converting enzyme (ACE) inhibitors are recommended given their 
broad protective benefits. Although animal studies have suggested beta-
blockers protect against aneurysm expansion and rupture, three clinical trails 
that examine the effects of propranolol on AAA growth failed to detect 
significant benefits on the progression of AAA (40). Of note, two cohort studies 
and meta-analysis suggested statins, the lipid-lowering drug, were beneficial to 
reducing AAA growth. 
 
The options for repair include surgical (transabdominal route or retroperitoneal 
route) and endovascular repair. Clinical trials indicated preventive endovascular 
or open surgical repair at early stage had no survival benefits compared to 
conservative treatment in combination with regular ultrasound, but associated 
with higher post-operative mortality (41). Based on these data, AAA repair is 
only recommended when the maximal diameter equals or exceeds 5.5 cm or 
when the growth rate of aneurysm is greater than 0.5 cm over 6 months. 
Endovascular repair is less invasive, associated with higher technical success 
rate (42-44) and improved mortality rate compared to elective surgical repair 
(45). However, studies failed to demonstrate long-term benefit of the 
endovascular approach versus surgical repair at the end of one or two years 
(46). 
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1.2 Overview of Animal Models of AAAs 
1.2.1 Genetically induced AAA 
Blotchy The blotchy mouse with alleles at the Mottled locus of the X 
chromosome have abnormal intestinal copper absorption that leads to a 
number of effects including a defect in the cross-linking of collagen and elastin. 
Elastin breakdown begins at an early age and progresses rapidly. Changes 
observed include replacement of elastin by fibroblasts and ground substance. 
Advanced lesions are characterized by infiltrates of inflammatory cells, 
hemorrhages and eventual ruptures of the aortic wall. As the disease 
progresses, observations include elastic fiber vacuolation and fragmentation, 
increased ground substance, fibroplasias and inflammatory cells infiltrates.  
 
THM (Transgenic mice overexpressing renin and AngII) The Tsukuba 
hypertensive mouse was produced by cross-breeding strains that expressed 
transgenes of human renin and angiotensinogen. The double transgenic mice 
have modest elevated blood pressure. There are no overt vascular pathologies 
in the transgenic mice until they are provided 1 % sodium chloride in drinking 
water. Then there is a dramatic increase in death during the first 10 days of salt 
administration caused by aortic ruptures in both thoracic and abdominal 
regions. The increased incidence of rupture is not associated with changes in 
blood pressure. 
 
Lox deficiency Lox deficient mice have an inability to crosslink both elastin 
and collagen. These mice develop to full term but are not viable because of 
aortic rupture. 
1.2.2 Chemically induced AAA 
Elastase-induced AAA To induce AAA by elastase, a catheter is introduced at 
the iliac bifurcation. Porcine pancreatic elastase is infused into the lumen and 
incubated within the infrarenal aortic segment for 5 minutes. Aortic wall 
diameter and structure remain stable for up to 7 days, after which a rapid and 
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significant increase occurs. By day 14, dilation is visible with extensive 
disruption of medial layers and profound inflammatory cell accumulation in the 
adventitial region. The AAA is defined by an increase in diameter of at least 
100% greater than the pre-perfused aorta.  
 
Calcium chloride-induced AAA To induce AAA by CaCl2, the infrarenal 
abdominal aorta is exposed and gauze soaked in CaCl2 is directly applied to 
the adventitia of this region for a period of time and then removed. CaCl2-
induced AAA formation has been reported to form between 2-12 weeks after 
application in rodents, dependent on mouse strains, exposure time and 
concentrations of CaCl2. Histological examination of the aorta reveals 
disruption of the elastic network within the media by calcium precipitation. Peri-
aortic application also induces inflammatory cell infiltration, including 
macrophages, neutrophils and lymphocytes to the aortic media and adventitia.  
1.2.3 AngII-induced AAA 
The AngII induced AAA model is currently the most commonly used animal 
model. AngII (1,000 ng/kg/min) is infused subcutaneously via mini-pumps for 28 
days. The initial studies were performed in hypercholesterolemic mice that were 
either LDL receptor -/- mice fed a western diet or apoE -/- mice fed either 
normal or a western diet. Subsequent studies have also demonstrated AngII 
infusion also could induce AAA formation in normolipidemic mice, however at 
much lower incidence than hypercholesterolemic mice. AngII-induced AAA 
formation is independent of the modestly increased systolic blood pressure 
during AngII infusion. AAA induced by chronic AngII infusion is exclusively 
located at the suprarenal aortic region. It exhibits progressive luminal 
expansion, macrophage accumulation throughout the aneurismal tissues, 
elastin fiber disruption accompanied by leukocytes infiltration, disorganized 
extracellular matrix deposition and aortic wall remodeling.  
1.2.4 Novel Mouse Model of AAA 
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Recently, new mouse models of AAAs have been reported. (47-49) Significant 
calcification deposits have been found in CaCl2-induced AAA mouse model 
with calcium phosphate (CaPO4) as the major component. The sequential 
application of CaCl2 and phosphate buffered saline (PBS) to the adventitial 
surface facilitate the CaPO4 crystals deposition in aortas which is associated 
with fragmentation of elastin layer and enhancement of apoptosis in the 
medium. This AAA model creates rapid and robust aneurysmal dilation and 
displays similar pathological and histological characteristics as CaCl2 but at a 
higher magnitude. (47)  
 
Another simplified but highly reproducible and less challenging AAA mouse 
model is peri-adventitial elastase model. The aorta is exposed and bathed in 
elastase for 10 minutes. Early dilation is observed and ensures adequate 
exposure to elastase. At day 14, significant expansion of the aorta is found in 
the area that was exposed to elastase and it is associated with degradation of 
elastin fibers, accumulation of macrophage (48). 
 
AngII-dependent TGF-β activity has been extensively investigated in 
experimental Marfan syndrome while its role in the AAA has not been 
elucidated.  A newly developed AAA mouse model demonstrated the 
neutralization of TGF-β made disease resistant C57BL/6 mice susceptible to 
AngII-induced AAA formation. This mouse model indicates the protective role of 
TGF-β activity during development of AAA.  
1.3 Characteristics of AngII-induced AAAs  
There is evidence that the renin angiotensin system contributes to experimental 
AAAs.  Inhibition of angiotensin-converting enzyme (ACE) or AT1 receptors 
reduces elastase-induced AAAs (50-53) or decellularise aortic xenograft-
induced AAAs (54) in rats and multiple mouse models (55). These findings 
highlight effects of the endogenous activation of AngII in AAA pathogenesis. 
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The most direct evidence from animal models is that AngII infusion leads to 
AAAs and aortic rupture in mice (56, 57), and conversely, AngII type 1 (AT1) 
receptor inhibition diminishes AngII-induced AAAs (58-60).  In the AngII-
induced AAA mouse model, constant AngII delivery was achieved by implanting 
mini osmotic pumps into the subcutaneous area of the flank.  A range of AngII 
infusion rates, from 500 - 2,500 ng/kg/min, have been used to induce AAAs (56, 
57, 61, 62). However, the most frequently used AngII infusion rate in 
hypercholesterolemic mice is 1,000 ng/kg/min (or 1.44 mg/kg/day) for a 
duration of 28 days (or 4 weeks) (57, 63), while a prolonged infusion for 84 
days (or 12 weeks) were also reported (64-66). Since the initial report, this 
mouse model has been reproduced by more than 40 laboratories.  One 
significant feature of AngII-induced AAAs in mice is its location in the 
suprarenal aortic region.  This location was also noted in other chemically 
induced experimental AAAs such as hypercholesterolemia and aldosterone (7, 
67, 68), and some genetically manipulated mouse models (69). This differs 
from the infrarenal location that is most common in humans.  The mechanistic 
basis for the location of AAAs is unclear in both humans and mice.  Although it 
is unknown why AAAs locate to the suprarenal aortic region in mice have not 
been defined, the potential hemodynamic differences between mice and 
humans may be attributed to the different locations since humans are biped, 
whereas mice are quadruped. 
  
AngII-induced AAAs recapitulate many pathological features of human AAAs 
including elastin breaks, extracellular matrix degradation, inflammatory cell 
accumulation and aortic rupture.  One apparent pathological difference is that 
intraluminal thrombus is present in human AAAs, whereas intramural 
hemorrhage has been observed in AngII-induced AAAs in mice (70, 71). 
1.3.1 Pathological Features of AngII-induced AAAs 
Human AAAs are heterogeneous both within a single aneurysmal tissue and at 
different stages during its development.  Consistent with human AAAs, AngII-
induced AAAs are highly heterogeneous, thereby providing an important tool to 
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understand potential processes from the initiation to advanced stages of AAAs 
(72). In the past decade, understanding of the complex pathologies of AngII-
induced AAAs in mice has provided insights into defining the complex 
mechanisms of AAAs in humans. 
There are a scant number of macrophages in the adventitia and the presence 
of this cell type is very rare in the medial layers of a normal aorta in mice.  As 
early as 48 hours after starting infusion of AngII, profound accumulation of 
macrophages in both adventitial and medial layers are detected that are 
frequently accompanied by elastin fiber breaks (64). At the same time, 
diminished vessel wall compliance and significant luminal dilation are also 
observed by ultrasonography (73). The rapid expansion phase of AAA 
progression occurs within 10 days (64, 73). Another significant feature in this 
period is frequent aortic rupture (approximately 10 - 30%) due to transmural 
medial rupture that fails to constrain blood within the adventitia.  If bleeding is 
constrained by the adventitia, thrombi form surrounding the ruptured media. In 
addition to pronounced accumulation of red blood cells, accumulation of 
macrophages at the site of medial rupture and the surrounding adventitia is 
also profound.  Thrombi have largely resolved after 28 days of AngII infusion, 
accompanied by remarkable remodeling that is characterized by continuous 
leukocyte infiltration, disorganized collagen deposition, and formation of 
neomicrovessels (64, 65). Both T and B lymphocytes are also detected in 
aneurysmal tissues (57, 64). 
Continuous AngII infusion beyond the initial rapid lumen expansion that occurs 
in the initial 10 days leads to slowly progressive luminal expansion as 
demonstrated by both real-time in vivo measurements using ultrasonography 
and ex vivo measurement after termination (64-66, 73). After infusion of AngII 
for 84 days, thrombi have usually resolved completely, while remodeling of 
extracellular matrices, expanded lumen, and thinner aortic walls are more 
pronounced.  Aortic rupture rate is also increased at more advanced stages 
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(>20% after 28 days of infusion as noticed in our recent study) (65). Also similar 
as reported in humans, atherosclerotic lesions are frequently detected in 
hypercholesterolemic mice with prolonged AngII infusion.  Of note, adventitial 
thickening with normal or even smaller luminal diameter both proximally and 
distally around intact media is apparent.  The heterogeneity of AngII-induced 
AAAs requires careful consideration in selecting tissue sections to provide 
insights into mechanisms. 
1.3.2 Associations of AngII-induced AAAs with Risk Factors Identified in 
Humans 
1.3.2.1 Gender  
In agreement with the male gender preference in humans, the incidence of 
AngII-induced AAAs is 4-fold higher in male mice (74-78). It appears that 
androgen augments AngII-induced AAAs, whereas effects of estrogen in 
protection of AngII-induced AAAs remain to be clarified (74-77, 79). Castration 
of male apolipoprotein E (apoE) -/- mice to remove endogenous androgen 
resulted in reductions of AngII-induced AAAs that was comparable to age-
matched AngII-infused female apoE -/- mice (74, 75). Particularly interesting, 
adult females had high incidence of AngII-induced AAAs that was equivalent to 
male mice if they were administered testosterone on the first day after birth 
(77). Conversely, exogenous estrogen administration to AngII-infused male 
apoE -/- mice reduced incidence of AngII-induced AAAs (79). However, 
diminished endogenous estrogen by ovariectomy in female AngII-infused apoE 
-/- mice did not augment AAAs (74).  Although manipulations of sex hormones 
in AngII-infused mice provide insights into understanding effects of sex 
hormones on AAA development, molecular mechanisms that contribute to this 
effect are unclear. 
1.3.2.2 Aging 
Since one initial study used apoE -/- mice at the age of 6 months (57), many of 
the published studies also used this mouse model at similar ages.  Infusion of 
AngII at 1,000 ng/kg/min for 28 days in male apoE -/- mice at the age of 6 
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months or older led to AAA formation at 80 - 100%.  In later experiments, 
investigators reported that AngII-induced AAA incidence was also above 80% 
in apoE -/- mice at the age of 2 - 3 months (80, 81).  Therefore, currently there 
is no literature evidence that aging is a risk factor for AngII-induced AAAs. 
1.3.2.3 Smoking 
Smoking is associated with the presence of AAAs in humans (82). 
Epidemiological studies have demonstrated consistently that smoking is a 
positive risk factor for AAAs in humans (83-87). Molecular mechanisms by 
which smoking augments AAAs were explored using the AngII-infused mouse 
model.  In one study, apoE -/- mice were exposed to cigarette mainstream 
smoking that mimics the human heavy smoker status (88). Mice were infused 
with AngII 1000 ng/kg/min for 4 weeks, and then separated into two groups to 
receive AngII 500 ng/kg/min and either control (no smoking) or cigarette 
mainstream smoking for another 4 weeks.  Therefore, contribution of smoking 
to progression, not the initiation of AAAs, was studied.  At the endpoint, AAA 
incidence was not significantly different between mice with and without smoking 
exposure (88). This study did not report aortic rupture rate or compare maximal 
aortic diameters between mice not or exposed to smoking.  A later experiment 
used a subcutaneous pellet to release nicotine, a putative major toxin in 
cigarettes (89), and found that it augmented AngII-induced AAAs via regulating 
microRNA (miR)-21 that act as a key modulator of proliferation and apoptosis of 
vascular smooth muscle cells.  A single study also reported that subcutaneous 
infusion of nicotine alone induced AAAs in apoE -/- mice that had comparable 
pathological changes as AngII-induced AAAs, although the incidence is much 
lower (90). In addition to nicotine, 3,4-benzopyrene, another compound in 
cigarette smoke, was found to augment AngII-induced AAAs in C57BL/6 mice 
(91).  It is unclear why single components in cigarette smoke augmented AngII-
induced AAAs, while entire components did not have this augmentation effect.  
In the initial study using cigarette mainstream smoking (88), there are two 
potential differences from the other studies.  First, this experiment determined 
whether smoking augmented the progression, not the formation, of AngII-
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induced AAAs.  Second, it is unclear whether AAA incidence was different 
when mice were grouped to receive cigarette smoking, or not, since no 
ultrasonography was used to stratify mice.  Further studies are necessary to 
both replicate these experiments and explore potential discrepancies on 
smoking effects between human AAAs and AngII-induced AAAs in mice. 
1.3.2.4 Obesity 
The literature has been inconsistent regarding associations between AAAs and 
obesity in humans, with some showing potential associations (92-96), and 
some failing to define significant associations (97, 98). Adipokines, including 
adiponectin and leptin, regulate functions of adipose tissues, and impairment of 
adipokines results in dysfunction of adipose tissues in obese individuals.  
Adiponectin, an anti-inflammatory adipokine, is solely derived from adipocytes.  
In apoE -/- mice infused with AngII 1,000 ng/kg/min, deficiency of adiponectin 
augmented AngII-induced AAAs without affecting body weight (99).  Different 
from adiponectin, leptin is closely associated with body weight change.  Leptin 
deficiency leads to profound body weight gain in mice (100).  Leptin deficiency 
augmented AngII-induced AAAs in C57BL/6 mice (101). However, it appears 
that this is not a leptin-specific effect since diet-induced obesity also augmented 
AngII-induced AAAs in C57BL/6 mice that was comparable to AAAs in leptin-
deficient mice (101, 102). In contrast to the effects of whole body deficiency of 
leptin, local application of leptin surrounding the abdominal aorta augmented 
AngII-induced AAAs (103).  These findings implicate that leptin plays differential 
roles in AngII-induced AAAs locally versus systematically.  Therefore, similar to 
the confusing associations in human AAAs, contributions of obesity as well as 
its related inflammatory changes to AAAs require systematic determination in 
future studies. 
1.3.2.5 Dyslipidemia 
In several small observational studies in humans, AAAs showed positive 
associations with plasma LDL-cholesterol concentrations and negative 
associations with plasma high-density lipoprotein (HDL)-cholesterol 
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concentrations (104, 105), whereas other studies did not find associations of 
AAAs with either LDL- or HDL-cholesterol concentrations (106-109). Although 
there are no established associations between dyslipidemia and AAAs, 
administration of statins, a commonly used class of drugs to reduce plasma 
LDL cholesterol, to patients with AAAs reduced aortic expansion rate in 
observational studies (110-112). Therefore, the literature supports potential 
contributions of dyslipidemia to AAA development in humans. 
 
Infusion of AngII to promote AAAs was first reported in LDL receptor -/- mice 
fed a diet enriched with both saturated fat and cholate (56). The infusion rate of 
AngII was 500 ng/kg/min. Subsequently, it was found that infusion of AngII into 
apoE -/- mice fed a normal laboratory diet also led to AAAs (57).  
Apolipoprotein (apo)B-containing lipoproteins are the predominant lipoprotein in 
these hypercholesterolemic mouse models.  However, later studies have 
demonstrated that AngII-induced AAAs also occur in normocholesterolemic 
mice (113-116). Although there are no side-by-side comparisons, it appears 
that the incidence is approximately 5-fold or higher in hypercholesterolemic 
mice than in normocholesterolemic mice (113-116).  One speculation regarding 
high incidence of AngII-induced AAAs in hypercholesterolemic mice is that 
atherosclerosis is associated with augmentation of AAAs, since the association 
between atherosclerosis and AAAs were also implicated in human 
observational studies.  However, multiple genetic mouse models have provided 
evidence about the dissociation between atherosclerosis and AngII-induced 
AAAs (61, 78, 117). 
 
Although deficiency of apoE promotes AngII-induced AAAs in mice, 
associations between genotypes of apoE and AAAs in humans are uncertain. 
In one study that screened apoE genotypes in 57 men with small AAAs, 
patients with E3E4 genotype had less aortic expansion, compared to patients 
with E3E3 genotype during an interval of 2-4.5 years (118). However, a study 
having investigated apoE genotypes in 640 men with small AAAs failed to 
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detect associations between apoE genotypes and growth of AAAs in a 4-year 
follow-up (119). These two studies did not compare plasma cholesterol 
concentrations in patients with different apoE genotypes. 
 
Statins do not change plasma cholesterol concentrations in mice.  One study 
reported that simvastatin reduced AngII-induced AAAs in apoE-/- mice (120) 
fed a saturated fat-enriched diet without changing plasma cholesterol 
concentrations.  In contrast, other studies found that simvastatin, rosuvastatin, 
or atorvastatin had no significant effects on AAAs in AngII-infused apoE -/- mice 
or LDL receptor -/- mice (121-123).  
 
Fenofibrate is used to reduce plasma triglycerides concentrations in humans.  
One study reported that fenofibrate reduced AngII-induced AAAs in apoE -/- 
mice (122). In addition to associations of AngII-induced AAAs with 
hypercholesterolemia, a recent study has provided evidence that administration 
of native or reconstitutive HDL diminishes AngII-induced AAAs in apoE -/- mice 
(124). This study infers a potentially important role of this apoAI-containing 
lipoprotein in development of AngII-induced AAAs. 
 
The current literature implicates potential and complex associations between 
dyslipidemia and AngII-induced AAAs.  It will be important to explore roles of 
both apoAI- and apoB-containing lipoproteins using appropriate genetic and 
pharmacological approaches in AngII-infused mice. 
1.3.3 Potential Protective Factor for AngII induced AAAs 
1.3.3.1 Diabetes 
Diabetes contributes to augmentation of atherosclerosis. In contrast, several 
studies have described diabetes being negatively associated with the presence 
of human AAAs (125). The mechanisms of reduced AAAs in diabetes have not 
been determined.  There is only one study that has investigated the contribution 
of diabetes to AngII-induced AAAs (126). ApoE -/- mice were injected with 
streptozotocin intraperitoneally to induce hyperglycemia. Subsequently, AngII 
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(1,000 ng/kg/min) was infused for 28 days. There was a modest reduction at 
day 14 and 21 of AngII-induced aortic dilation in mice with hyperglycemia, as 
determined by ultrasonography (126). Mechanisms by which hyperglycemia 
reduced aortic dilation have not been explored. 
1.3.3.2 Irradiation 
Irradiation suppresses immune response, and has been demonstrated to 
attenuate inflammation in humans (127). Studies by Gavish et al. have provided 
evidence that irradiation diminishes AngII-induced AAAs in apoE -/- mice that 
were associated with enhanced extracellular matrix (ECM) reinforcement and 
modification in response to the inflammatory process (128, 129). 
1.3.4 Genetic and Pharmacological Manipulations of AngII-induced AAAs 
The renin angiotensin system contributes to development and progression of 
AAAs in mice.  Using AngII-induced AAA mouse model, it has been defined 
that excessive AngII leads to activation of AngII type 1 (AT1) receptor.  In mice, 
AT1 receptor has two subtypes, AT1a and AT1b.  There have been consistent 
demonstrations that AT1 receptor antagonism, using pharmacological 
approaches, reduces AngII-induced AAAs (58, 60, 130). This is attributed to 
interactions between AngII and AT1a receptor in mice because whole body 
deficiency of AT1a receptor ablates the development of AngII-induced AAAs 
(131), whereas AT1b receptor (132) or angiotensin II type 2 (AT2) receptor 
(133) deficiency had no effects on AngII-induced AAAs.  Studies of mice that 
had AT1a receptor depletion on leukocytes, endothelial cells, or smooth muscle 
cells did not define a single cell type that played a critical role in AngII-induced 
AAA development (131, 134), implicating orchestrated contributions of multiple 
cell types in the interaction of AngII and AT1a receptor to promote AAAs. 
  
AngII interacts with AT1a receptors to promote AngII-induced AAAs.  As 
reviewed by Mehta and Griendling (135), AngII binding to AT1a receptors 
activates a broad spectrum of downstream cascades that influence 
cardiovascular pathophysiology.  Many of these downstream signalings have 
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been involved in molecular mechanisms of AAAs, such as activation of 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase to generate 
reactive oxygen species (ROS) or mitogen-activated protein kinase (MAPK) 
signaling pathway including extracellular signal-regulated kinase (ERK1/2) and 
c-Jun N-terminal kinase (JNK) (55). 
 
In addition to understanding the renin angiotensin system related mechanisms, 
AngII-induced AAAs have been used to explore molecular mechanisms by 
multiple genetic or pharmacological manipulations and seek for potential non 
invasive therapeutic strategies.  Microarray analysis discovered that a complex 
network profiling is involved in AngII-induced AAAs. This section focuses on 
mechanistic explorations including inflammation, disrupted homeostasis of 
extracellular matrix related factors, vascular oxidative stress and newly 
emerged mechanisms such as microRNA-mediated changes 
1.3.4.1 Inflammation Related Factors  
1.3.4.1.1 Macrophage and Related Inflammatory Components 
Many inflammatory cell types have been identified in AAA tissues, and 
macrophages are the largest subpopulation of leukocytes detected through all 
stages of AAAs (70). In mice infused with AngII, macrophage accumulation in 
both medial layers and the adventitia is observed within 48 hours after initiating 
AngII infusion, and is persistent from the initial stage through advanced stages 
(64, 65, 102, 103). The spleen is proposed to act as a reservoir for mobilizing 
monocytes/macrophages into the circulation in response to AngII stimulation. 
Impaired mobilization and accumulation of monocytes protected against AngII-
induced AAA development (136). Infiltration of macrophages from the 
peripheral blood into the aortic wall requires passing through the endothelial 
barrier.  CD31, an immunoreceptor that is abundant on endothelial cells, plays 
a critical role in monocyte-endothelial adhesion.  Inhibition of CD31 by 
administering a murine CD31-derived peptide profoundly reduced incidence of 
AngII-induced AAAs in apoE -/- mice, which suppressed macrophage activation 
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(137). CCR2 and monocyte chemoattractant protein-1 (MCP-1) interactions are 
important for monocyte chemotaxis and many macrophage-mediated 
inflammatory responses.  Deficiency of CCR2 globally, or in bone marrow-
derived cells in mice, diminished AngII-induced AAAs (55). Infusion of 
everolimus, a rapamycin inhibitor, suppressed CCR2-expressing monocytes, 
and reduced AngII-induced AAAs in apoE -/- mice (138). While no studies have 
been performed using the available MCP-1 deficient mice, inhibition of whole 
body MCP-1 signaling through plasmid delivery of a MCP-1 dominant negative 
form did not reduce AngII-induced AAAs (139). MKEY is a mouse CCL5-based 
synthetic cyclic peptide that inhibits the proinflammatory interaction between 
CCL5 and CXCR4 thereby attenuating monocyte recruitment (140). 
Administration of MKEY only reduced maximal aortic diameter on day 3 during 
AngII infusion as measured by ultrasound (60, 141), but had no effects on 
incidence of AngII-induced AAAs at the endpoint in apoE -/- mice (60), 
implicating rapid and transient effects of CCL5-CXCR4 interaction in AngII-
induced AAAs. 
 
Macrophage accumulation is accompanied by activation of many inflammatory 
factors that are involved in immune responses.  Myeloid differentiation factor 88 
(MyD88) is an important adaptor protein that regulates macrophage functions in 
innate immunity. Genetic deficiency of this protein globally or in bone marrow-
derived leukocytes reduced AngII-induced AAAs in both LDL receptor -/- and 
apoE -/- mice (81), CD14 is a glycophosphatidylinositol-linked surface protein 
pattern recognition receptor, acting via MyD88 and other proteins to activate 
the innate immune system. Comparable to MyD88 deficiency, deficiency of 
CD14 diminished aortic macrophage infiltration and AngII-induced AAA 
formation in apoE -/- mice (142). Telomerase reverse transcriptase (TERT) is 
the enzyme that stabilizes telomeres, and is abundant in macrophages.  TERT 
deficiency in macrophages attenuated AngII-induced AAAs in mice (143). 
Syndecan-1 is a cell surface heparan sulfate proteoglycan that modulates 
proinflammatory and proteolytic processes within the vascular wall.  Deficiency 
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of syndecan-1 led to profound increases of AAA incidence and rupture rate in 
apoE -/- mice infused with AngII at 500 ng/kg/min for 2 weeks (144). Notch-1 
encodes a single-pass transmembrane receptor.  Notch-1 haploinsufficiency or 
pharmacological inhibition of Notch-1 by DAPT (N-[N-(3,5-Difluorophenacetyl)-
L-alanyl]-S-phenylglycine t-butyl ester) reduced AngII-induced AAAs in apoE -/- 
mice (145). Notch-1 haploinsufficiency in bone marrow-derived cells reduced 
AngII-induced AAAs (145). Dibenzazepine, a Notch (-secretase inhibitor, also 
reduced AngII-induced AAAs in apoE -/- mice (146). 
 
Transforming growth factor (TGF)-$ is a critical cytokine in many inflammatory 
processes that is secreted from many cells types. Cyclosporine A has strong 
anti TGF-$ effects.  In an AAA patient treated with cyclosporine A, greatly 
accelerated progression of aortic expansion was noted (147), implicating 
potential detrimental effects of TGF-$ inhibition on the progression of AAAs.  
Consistent with this clinical case report, systemic blockade of TGF-$ activity 
augmented AngII-induced AAAs in mice and was associated with enhanced 
vascular inflammation (49). Depletion of monocytes in circulation by clodronate-
containing liposomes in mice administered AngII and TGF-$ neutralizing 
antibody attenuated AAA formation and aortic rupture (49), implicating 
important roles of monocytes in AAAs induced by AngII infusion with 
simultaneously inhibiting TGF-$. 
 
These studies, using genetic and/or pharmacological manipulations, 
demonstrate that both the presence and function of macrophages are critical in 
the development of AngII-induced AAAs; however, it is unclear whether 
inhibition of macrophage numbers or specifically targeting certain components 
to inhibit macrophage functions would prevent or improve AAAs in humans.  
1.3.4.1.2 Lymphocytes and Related Inflammatory Components 
Lymphocytes are present in human AAAs (148). Both T and B lymphocytes are 
also detected in AngII-induced AAAs (57, 64). Recombination-activating gene 
(Rag-1 and -2) proteins are crucial for immunoglobulin and T-cell receptor gene 
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recombination. Genetic deletion of either Rag in mice leads to deficiency of 
mature T and B lymphocytes.  Despite striking effects of Rag-1 deficiency on 
lymphocyte functions, it did not influence AngII-induced AAAs in apoE -/- mice 
(114). In contrast, Rag-2 deficiency reduced AngII-induced AAA formation 
(136). It should be noted that these two Rag proteins have different expression 
levels during selected stages of T and B lymphocyte antigen receptor assembly 
(149, 150), implicating potentially different effects in AngII-induced immune 
responses, thereby differential effects on AngII-induced AAAs. In addition to 
general changes of lymphocytes, changes in number or function of some 
subtypes of lymphocytes also influenced the development of AngII-induced 
AAAs.  For example, CD4+CD25+ regulatory T cells are a small subpopulation 
of T cells that play a critical role in maintaining immune homeostasis.  
Deficiency of this subtype of T lymphocytes, despite representing a small 
portion, led to multiple pathological immune responses (151). Consistent with 
the critical role of this T lymphocyte subtype in immunological tolerance, 
depletion of regulatory T cells using an anti-CD25 monoclonal antibody 
significantly increased the incidence and severity of AngII-induced AAAs in 
C57BL/6 mice (152), while transfer of regulatory T cells into apoE -/- mice 
attenuated AngII-induced AAAs (153). 
 
Roles of many cytokines and chemokines secreted by lymphocytes have been 
implicated in the development of AAAs.  Th1 cells secrete interleukin (IL)-1, IL-
6, tumor necrosis factor (TNF)-" and interferon (, and Th2 cells secrete IL-5.  
TNF-" is one of the landmark cytokines in many inflammatory responses.  
TNF-" is increased in plasma and AAA tissues from patients with AAAs (154-
157). TNF-"-converting enzyme (TACE or ADAM17) and osteoprotegerin, a 
secreted glycoprotein member of the TNF receptor superfamily, are enhanced 
in human AAAs (158). Although the presence of TNF-" related components 
implicates an important role of TNF-" and its related factors in AAAs, 
deficiency of the p55 TNF receptor did not influence AngII-induced AAAs in 
LDL receptor -/- mice (159). 
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Interferon-( and CXCL10, an interferon-( inducible T-lymphocyte 
chemoattractant, were increased in aneurysmal tissues of AngII-infused mice 
(160). Deficiency of either component led to augmentation of AngII-induced 
AAAs (160). Consistent with these findings, deficiency of a critical molecule in 
interferon-( signaling, signal transducer and activator of transcription (STAT)1, 
also augmented formation of AngII-induced AAAs (161). In mice with CXCL10 
deficiency, concomitant decreases of T lymphocytes and interferon-( 
production were noticed in aneurysmal tissues, accompanied by increases of 
TGF-$.  In agreement with these results, administration of an anti-TGF-$ 
neutralizing antibody reduced AngII-induced AAAs in CXCL10 deficient mice 
(160). It is unclear why inhibition of TGF-$ in mice with CXCL10 deficiency 
yielded conflicting findings with inhibition of TGF-$ augmenting AngII-induced 
AAAs in wild-type mice (49). 
 
IL-5 is a cytokine secreted by Th2 cells.  AngII infusion into apoE -/- mice led to 
a profound and peak increase of IL-5 in the aortic wall within 7 days of AngII 
infusion, and then slowly decreased back to the baseline level during 28 days 
of AngII infusion (162). It appears that this initial, transient increase of IL-5 is 
critical to AngII-induced AAA formation because administration of TRFK-5, a 
monoclonal antibody against IL-5, into AngII-infused apoE -/- mice led to 
reductions of AAAs (162). 
 
In general, effects of cytokines and chemokines produced or stimulated by 
lymphocytes on AngII-induced AAAs, as reported in the literature, are either 
modest or not consistent with their roles in inflammation. 
1.3.4.1.3 Orchestrations of Multiple Cell Types or inflammatory 
components 
In addition to leukocyte infiltration, roles of mast cells have been recognized in 
AAA tissues from humans (163, 164) and animal models (165). This cell type 
synthesizes and releases multiple proteases and inflammatory mediators, 
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thereby playing a critical role in inflammation and immunity.  KitW-sh/W-sh mice 
are considered a mast cell deficient mouse model, although these mice have 
multiple issues in addition to deficiency of mast cells.  A recent study found that 
incidence and severity of AngII-induced AAAs were profoundly lower in KitW-
sh/W-sh mice with an apoE -/- background (166). Particularly interesting, adoptive 
transfer of bone marrow-derived mast cells from CCR2 and apoE compound 
deficient mice retained the protective effects on AngII-induced AAAs in KitW-sh/W-
sh mice, whereas adoptive transfer of bone marrow-derived mast cells from 
apoE -/- mice led to augmented infiltration of macrophages, T lymphocytes, and 
MHC class II-positive cells in KitW-sh/W-sh mice, and thereby augmentation of 
AngII-induced AAAs (166). 
 
Immunoglobulin E (IgE) activates mast cells.  Pharmacological inhibition of IgE 
or whole body deficiency of its receptor Fc,R1 led to profound reductions of 
AngII-induced AAAs (167). In addition to mast cells, interactions of IgE with 
Fc,R1 activated macrophages and CD4+ T cells (167). In agreement with 
crucial roles of Fc,R1 in these cell types, adoptive transfer of mast cells, 
macrophages, or CD4+ T cells individually into Fc,R1 -/- mice did not change 
AngII-induced AAAs (167). 
 
STAT3 is a transcription factor that can be activated by multiple 
proinflammatory factors in many types of leukocytes.  AngII infusion led to T 
helper 17 (Th17) cell recruitment into the aortic wall, which was mediated by 
activation of IL-6-STAT3 signaling, and IL-17A was one major cytokine 
secreted by Th17 cells (168). As a consequence, deficiency of IL-6, genetic or 
pharmacological inhibition of IL-17A, or pharmacological inhibition of STAT3 
reduced AngII-induced AAAs (168). In contrast to this finding, another study 
reported that deletion of STAT3 signaling via overexpression of suppressor of 
cytokine signaling 3 (SOCS3) reduced IL-17, but augmented AAAs induced by 
AngII infusion and injections of TGF$ neutralizing antibody (169). It remains to 
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be defined whether these conflicting findings are due to different mechanisms 
between AngII alone versus AngII-TGF$ interaction. 
 
Complement activation through multiple pathways plays an important role in 
immune responses. The formation of membrane attack complex is the result 
product of complement activation.  CD59 inhibits the membrane attack 
complex.  A recent study found that overexpression of CD59 protected against 
AngII-induced AAAs in apoE-/- mice (170), associated with changes of matrix 
metalloproteases (MMP)2 and 9 as well as attenuated inflammation.  
 
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
transcriptional factors with multiple functions in energy metabolism and 
vascular biology.  GW501516, an activator of PPAR*, reduced AngII-induced 
AAAs in apoE -/- mice (171). Drugs in the class of thiazolidinediones such as 
pioglitazone and rosiglitazone are used to reduce blood glucose in diabetic 
patients.  It is also well known that these drugs activate PPAR(.  Pioglitazone 
or rosiglitazone reduced AngII-induced AAAs in apoE -/- mice (122, 172). 
However, administration of pioglitazone to LDL receptor -/- mice did not 
attenuate AngII-induced AAAs (173). In accord with this finding, deficiency of 
PPAR( in smooth muscle cells did not affect AngII-induced AAAs (173). It is 
unclear whether PPAR( expressed in other cell types would contribute to AngII-
induced AAAs since systemic administration of pioglitazone did not attenuate 
AngII-induced AAAs in mice with smooth muscle cell-specific PPAR( deficiency 
(173). Although thiazolidinediones activate PPAR(, there is no direct evidence 
that this class of drugs attenuates AngII-induced AAAs by activating PPAR(.  It 
is also unclear why pioglitazone reduced AngII-induced AAAs in apoE -/- mice 
(122), but not in LDL receptor -/- mice (173), although the dose of pioglitazone 
used in LDL receptor -/- mice was lower (20 mg/kg/d in diet) (173) than in apoE 
-/- mice (50 mg/kg/d in drinking water) (122). 
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Mesenchymal stem cells are a small population of non leukocytic stem cells. 
These cells suppress immunoreactivity of T cells and inhibit macrophage-
mediated inflammation.  Application of bone marrow-derived mesenchymal 
stem cells through laparotomy or intravenous injections attenuated AngII-
induced AAAs (174, 175). 
 
Overall, the evidence is consistent with inflammatory cells and responses play 
a crucial role in development of AngII-induced AAAs.  However, currently there 
has no clinical evidence whether inhibition of inflammatory cell number or 
functions would improve AAAs in humans. Using cell-specific deficient mice 
that had AT1a receptor depletion on leukocytes, endothelial cells, or smooth 
muscle cells did not define a single cell type that played a critical role in AngII-
induced AAA development (131, 134), implicating orchestrated contributions of 
multiple cell types in the interaction of AngII and AT1a receptor to promote 
AAAs. 
1.3.4.2 Extracellular Matrix Related Factors 
Extracellular matrix (ECM), composed of collagen and elastin fibers, are 
essential in maintaining normal aortic structure.  Mechanisms by which ECM 
related factors contribute to AAAs as implicated in reported studies include 
disrupted homeostasis of ECM degradation and subsequent loss of vessel wall 
integrity.  Inflammatory responses are also pronounced during changes of 
vessel wall integrity.  Many components in the ECM family have been studied in 
AAA formation in AngII-infused mice.  Osteopontin is a secreted extracellular 
matrix protein present in aortic tissue (176). Deficiency of osteopontin globally 
or specifically in bone marrow-derived cells reduced AngII-induced AAAs (62). 
MMPs and tissue inhibitors of metalloproteinases (TIMPs) maintain structural 
integrity of the aortic wall. Several MMPs are present in human AAAs.  In a 
recent meta-analysis, 8 case-control studies were pooled to determine whether 
circulating MMP9 concentrations were associated with AAA presence in 
humans (177). Although higher plasma MMP9 concentrations were associated 
with AAA presence, it is worth noting that there were broad value ranges of 
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MMP9 for both AAAs (30 - 750 ng/L) and non-AAAs (9 - 680 ng/L) (177). Many 
studies reported that AngII infusion increased MMP9 in aortic tissues (a few 
examples (66, 114, 138, 178)). Although deficiency of MMP9 prevented 
elastase-induced [19] and calcium chloride-induced AAAs in mice (179), 
deficiency of MMP9 in AngII-induced AAAs in mice has not been reported.  
MMP2 deficiency in C57BL/6 mice did not affect AngII-induced AAAs (180). In 
contrast, TIMP3 augmented AngII-induced AAAs in C57BL/6 mice, and MMP2 
deficiency beyond TIMP3 deficiency further augmented AngII-induced AAAs in 
C57BL/6 mice (181).  Currently, there has no specific pharmacological 
inhibitors for MMP9 or MMP2.  Doxycycline is an antibiotic, which is also known 
as a pharmacological inhibitor of a broad range of MMPs.  Preventive 
administration of this drug either reduced (78, 182) or had no effect (60) on 
AngII-induced AAAs in mice.   
 
Cathepsins K, L, and S are elastases that are activated in remodeling of arterial 
wall.  These cathepsins have been implicated in human AAAs (183). Deficiency 
of cathepsin S reduced AngII-induced AAAs in apoE-/- mice (184), whereas 
deficiency of cathepsin K had no effects on AngII-induced AAAs (185). Cystatin 
C is an endogenous inhibitor of cysteinyl cathepsins. Deficiency of cystatin C 
augmented AAAs in AngII-infused mice (186). 
 
Caspases and calpains belong to the family of cysteine proteases.  
Pharmacological inhibition of either caspase [163] or calpain (187, 188) 
reduced AAAs in AngII-infused mice, implicating that these cysteine proteases 
are contributors to AngII-induced AAAs.  
 
Granzyme B, chymase, and urokinase-type plasminogen activator (uPA) are 
serine proteases.  Deficiency of granzyme B (189) or pharmacological inhibition 
of chymase attenuated AngII-induced AAAs in apoE -/- mice (190). 
Plasminogen activator inhibitor-1 (PAI-1) is a natural inhibitor of uPA.  One 
study reported that increased PAI-1 prevented AngII-induced AAAs in apoE-/- 
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mice through local delivery recombinant adenovirus containing human PAI-1 
gene (intra-adventitial injection), but not through systemic delivery (tail vein 
injection) (191). The mechanism leading to the different response to local 
versus systemic administration of PAI-1 was not defined.  Additionally, effects 
of uPA on AngII-induced AAAs have not been consistent.  An initial study found 
that uPA deficiency attenuated AngII-induced AAAs in both apoE -/- mice and 
C57BL/6 mice (113). Conversely, neither uPA nor uPA receptor deficiency 
changed aortic dilation in AngII-infused LDL receptor -/- mice (114). In contrast, 
uPA deficiency led to increased aortic rupture in LDL receptor -/- mice (114). It 
appears that this finding is not due to different mouse strains used in the two 
studies since our study also found that deficiency of uPA had no effects on 
AngII-induced AAAs in C57BL/6 mice. 
 
It is well known that ECM related factors play essential roles in the 
development and progression of AAAs.  However, findings using AngII-induced 
AAAs have not consistently defined specific factors that would provide benefits 
in the treatment of AAAs.  The disappointing findings in the recent reported 
clinical trial (192) that doxycycline did not improve AAAs in humans provides a 
caveat in the current mechanistic explorations and we have a long way to 
discover or develop ideal targets to treat patients with AAAs (193). 
1.3.4.3 Phospholipid Related Factors 
Phospholipids contribute to maintaining cell membrane structure.  This class of 
lipids also plays important roles in inflammation.  Non-selective 
pharmacological inhibition of phospholipases reduced AngII-induced AAAs 
(194). Several critical components of arachidonic acid cascade have been 
studied in AngII-induced AAAs.  5-lipoxygenase (5-LO) is key component in 
biosynthesis of leukotrienes by catalyzing arachidonic acid.  Deficiency of 5-LO 
had no effect on AngII-induced AAAs in mice (195). A pharmacological inhibitor 
of 5-LO, MK-0591, did not change AngII-induced AAAs in apoE-/- mice (195), 
whereas another 5-LO inhibitor, LP105, reduced severity, but not aortic 
diameters of AngII-induced AAAs in apoE -/- mice (196). Leukotriene B4, 
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produced through 5-LO pathway, exerts its effects through a G protein-coupled 
receptor BLT1.  Genetic deficiency (197) or pharmacological inhibition (198) of 
BLT1 attenuated AngII-induced AAAs.  Considering the complexity of 5-LO 
signaling pathway, it is possible that BLT1 is a better target for inhibiting AngII-
induced AAAs.  Cyclooxygenase (COX) and its downstream pathway to 
generate prostaglandin E2 (PGE2), have also been detected in human AAAs 
(199). Genetic deficiency of COX-2 either reduced (200) or had no effects on 
AngII-induced AAAs (201). A specific pharmacological inhibitor of COX-2, 
celecoxib, reduced AngII-induced AAAs (115, 202). Microsomal PGE2 
synthase-1 (mPGES-1) is the enzyme to generate PGE2.  Deficiency of 
mPGES-1 reduced AngII-induced AAAs (203). Pharmacological inhibition (AE3-
208) (201, 204) or genetic depletion (EP4 +/-) of EP4, a PGE2 receptor, 
attenuated AAA formation in AngII-infused apoE-/- mice (204). However, 
deficiency of EP4 in bone marrow-derived cells increased AngII-induced AAAs 
(205).  
 
Phospholipases A2 (PLA2) are a group of enzymes that cleave phospholipids 
to generate lysophospholipids and free fatty acids.  Group V and group X 
secretory PLA2 have been studied in AngII-induced AAAs.  Genetic deficiency 
of group X, but not group V, secretory PLA2 attenuated AngII-induced AAAs in 
apoE -/- mice (206, 207). Plasma phospholipid transfer protein (PLTP) is a 
member of lipid transfer/lipopolysaccharide-binding proteins.  Whole body 
deficiency of PLTP reduced AngII-induced AAAs in apoE -/- mice, which was 
not attributed to its deficiency in bone marrow-derived cells (208). 
 
Although many phospholipid related factors are present in AAA tissues, there 
are conflicting findings regarding their roles in AngII-induced AAAs.  The 
associations between phospholipid related factors and the formation of AAAs 
remain to be unraveled.   
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1.3.4.4 Oxidation Related factors 
Oxidation contributes to a spectrum of diseases.  AngII promotes and 
augments oxidation in multiple cell types (209). Critical enzymes in the 
homeostasis of oxidation include catalase and NADPH oxidases (NOX). 
Reactive oxygen species are present in either circulation or diseased tissues in 
patients with AAAs (210, 211). Vitamin E, a recognized antioxidant that inhibits 
NOX, reduced AngII-induced AAAs in 24-week-old apoE-/- mice (212). 
However, this effect was not significant in 50-60-week-old apoE -/- mice when 
both vitamin E and vitamin C were administered (59). Later, studies using 
genetic mouse models found that global deficiency of p47phox, a cytosolic 
subunit of NOX, in apoE -/- mice (213), global or bone marrow cell specific 
deficiency of NOX2 in LDL receptor -/- mice (178) or global deficiency of NOX1 
in C57BL/6 mice (214) reduced AngII-induced AAAs.  In contrast to potential 
effects of NADPH on augmentation of AngII-induced AAAs, deficiency of 
catalase, an antioxidant enzyme, did not influence AngII-induced AAAs (215). 
Overall, similar to other mechanisms explored in AngII-induced AAA mouse 
model, contributions of oxidation to AAAs and the potential therapeutic effects 
have not been defined. 
1.3.4.5 MicroRNAs 
Since the discovery of microRNAs (miR), this class of single-strand small RNA 
molecules have been reported in many disease processes.  Multiple miRs were 
detected in circulation and aneurysmal tissues of patients with AAAs (216-218). 
One initial study reported that inhibition of miR-29 by locked nucleic acid-
modified antisense oligonucleotides prevented aortic dilation in 18-month-old 
C57BL/6 mice or 6-month-old apoE -/- mice within 7 days of AngII. However, 
inhibition of miR-29 did not maintain this beneficial effect after 28 days of AngII 
infusion (219). In subsequent studies from two research groups (216, 217) 
inhibition of a miR-29 subtype, miR-29b, did not prevent aortic dilation within 10 
- 14 days of AngII infusion, whereas this inhibition led to a modest reduction of 
luminal diameter, as measured by ultrasound or MRI, after 28 days infusion of 
AngII in apoE -/- mice at 10 weeks of age.  These findings were consistent with 
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overexpression of miR-29b modestly augmenting AngII-induced luminal dilation 
during 14 and 28 days of AngII infusion (216). 
miR-21 induces cell proliferation and diminishes apoptosis in AngII-induced 
AAAs (89). Overexpression of miR-21 prevented AAA formation, and inhibition 
of miR-21 augmented AAA formation (89). miR-24 suppresses chitinase 3-like 
1 mediated cytokine synthesis in macrophages and macrophage interaction 
with vascular smooth muscle cells and endothelial cells (220). Inhibition of miR-
24 augmented AngII-induced AAAs, whereas overexpression of miR-24 
reduced AngII-induced AAAs (220). miR-712, a murine-specific miR, and its 
human homolog miR-205 were upregulated in endothelial cells isolated from 
abdominal aortas in AngII-infused mice (218). Inhibition of miR-712 or miR-205 
reduced AngII-induced AAAs in apoE -/- mice.  In general, recent studies have 
provided insights into understanding contributions of miRs in the development 
of AAAs.  Mechanisms involve orchestration of inflammation, cell-cell 
interactions, extracellular matrix protein degradation, oxidation, and many other 
signaling pathway(221). It would be important to explore potential therapeutic 
benefits of these miRs. 
1.3.5 Regression of AngII-induced AAAs 
In the clinical environment, treatment is initiated in patients following detection 
of an established AAA.  The mechanisms or therapeutics discussed above are 
mostly manipulations that prevent AAA initiation, in which manipulations were 
performed prior, or simultaneous to initiation of AngII infusion.  One decade 
ago, a single study reported that SP600125, an inhibitor of JNK, regressed 
established AAAs induced by AngII infusion in apoE -/- mice (222) ApoE -/- 
mice were infused with AngII 1,000 ng/kg/min for 4 weeks, and then stratified 
by ultrasound into two groups to receive either vehicle or SP600125 for 8 
weeks.  Luminal diameter, as measured by ultrasound, was profoundly reduced 
by JNK inhibition (222). Unfortunately, despite the striking effects of JNK 
inhibition, this study has not been followed up by other research groups or 
translated into clinical investigations. 
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Recently several studies have explored therapeutic potentials in mice with 
established AAAs using similar method reported by the above study (222). In 
some studies, apoE -/- mice were infused with AngII 1,000 ng/kg/min for 4 
weeks to induce AAAs.  Mice were then stratified based on ultrasound 
measurements of suprarenal aortic diameters.  One study reported that a 
peptide against the leucine-serine-lysine-leucine (LSKL) sequence in 
thrombospondin prevented progression of AngII-induced AAAs (223). Another 
study reported that aliskiren administration, a renin inhibitor (50 mg/kg/d), led to 
attenuated progression of AngII-induced AAAs (224).  In this study, in the 
absence of AngII infusion, suprarenal aortas expanded continuously, which 
contradict recent studies showing that AAAs did not progressively expand if 
AngII infusion was discontinued after 4 weeks of AngII infusion (65, 223). 
Considering that accuracy of ultrasonographic measurements is largely user-
dependent, further experiments are necessary to directly measure maximal 
diameters of the suprarenal aorta using ex vivo images. 
There are another two recent studies (225, 226) that used similar method to 
induce AAAs.  However, mice were not stratified using ultrasound 
measurements, but were randomly assigned to different groups.  In one study, 
after the 4-week infusion of AngII, bone marrow-derived mesenchymal stem 
cells were injected intravenously into apoE -/- mice (225). Compared to control 
groups, aortic diameters were much smaller in mice injected with bone marrow-
derived mesenchymal stem cells after 2 or 4 weeks. However, aortic diameters 
were equally large between control and bone marrow-derived mesenchymal 
stem cells injected mice after 8 weeks (225). In another study, apoE -/- mice 
was infused with AngII 1,000 ng/kg/min for 45 days.  These mice were 
subsequently grouped randomly to receive normal laboratory diet, diet 
containing "-tocopherol or $-carotene, or both for 60 days.  "-tocopherol and 
$-carotene are considered to have anti oxidation effects.  Individual or 
combination of these two reagents led to significantly smaller diameters of 
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suprarenal aortas in apoE -/- mice (226).  Since it is unclear whether mice had 
equally established AAAs among study groups, it is hard to provide evaluation 
whether manipulations reported in these two studies had potential therapeutic 
benefits on established AAAs. 
While the above studies implicate potential beneficial effects of treating 
established experimental AAAs, two recent studies (66, 202) failed to show 
beneficial effects of two different treatment on established AAAs.  One study 
used apoE -/- mice infused with AngII 750 ng/kg/min for 3 weeks prior to 
celecoxib administration, a COX-2 inhibitor, for 5 weeks when AngII was 
infused continuously.  Compared to mice infused with AngII for 8 weeks alone, 
mice receiving celecoxib had smaller aortic diameters.  However, this 
parameter in mice receiving celecoxib was not different from those infused with 
AngII for 3 weeks alone, implicating that celecoxib does not regress established 
AAAs (202).  In another study, LDL receptor -/- mice fed a Western diet were 
infused with AngII 1,000 ng/kg/min for 4 weeks, and then ultrasound were 
performed.  Mice with established AAAs were stratified into two groups to 
receive either plain drinking water or doxycycline (100 mg/kg/d) in drinking 
water when AngII infusion was continued for another 8 weeks.  Doxycycline 
had no effects on the progression of AngII-infused AAAs (66). This result was 
supported by the recent clinical trial reporting that doxycycline had no beneficial 
effects on established AAAs in humans (192). Compared to studies showing 
“positive” results, these two “negative” studies performed continuous AngII 
infusion during the treatments.  Taken the findings of these current studies 
together, although there are hopes from these animal studies to treat 
established AAAs in humans, it would be important to follow standard protocols 
and well-designed experiments with proper controls and accurate 
measurements to ensure capability to replicate experimental findings before we 
can move forward with clinical trials.  
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Chapter Two: ApoB-containing Lipoproteins Augment AngII-induced 
AAAs in Male Mice 
This chapter is based on a manuscript published in “Arterioscler Thromb Vasc 
Biol. 2015 August;35(8):1826-34”, with Jing Liu as the first author. 
2.1 Introduction 
Abdominal aortic aneurysms (AAAs) are permanent dilations that portend the 
devastating consequence of aortic rupture.  AAA prevalence and severity have 
been associated with increased plasma cholesterol concentrations (84, 227). 
Several studies demonstrated that prevalence of AAAs was correlated 
positively with plasma low-density lipoprotein (LDL)-cholesterol concentrations 
and negatively correlated with plasma high-density lipoprotein (HDL)-
cholesterol concentrations (14, 104, 105, 107, 228, 229). However, other 
studies failed to demonstrate a relationship between either LDL- or HDL-
cholesterol concentrations and AAAs (106, 107, 109, 230). Overall, 
hypercholesterolemia has a poorly defined role in human AAAs and further 
clarification is needed on the function of specific lipoprotein fractions. 
Regardless of an undefined association between hypercholesterolemia and 
AAAs, statin administration is common for patients afflicted with AAA to reduce 
aortic expansion, which has beneficial effects in preventing progression of 
AAAs or improving related cardiovascular events (110, 112).  
Chronic subcutaneous infusion of angiotensin II (AngII) into mice is a commonly 
used model of AAAs (231). Initial studies using this model were performed in 
hypercholesterolemic mice that were either LDL receptor-/- fed a Western diet 
(56) or apolipoprotein (apo)E-/- fed either a normal or Western diet (57, 58). In 
addition to a substantial number of studies of AngII-induced AAAs using 
hypercholesterolemic mice (232) a small number of studies have demonstrated 
that AngII infusion induces AAA formation in normocholesterolemic mice (49, 
113-115, 232, 233), albeit at much lower incidence than in 
hypercholesterolemic mice.  Despite the potential role of hypercholesterolemia 
in formation of AngII-induced AAAs, effects of specific lipoprotein fractions in 
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experimental AAA development have received sparse attention.  One study 
reported that increased plasma HDL-cholesterol concentrations by daily 
subcutaneous administration of human HDL (10 mg/kg/day of apoAI) reduced 
AngII-induced AAAs in apoE-/- mice (124). Injection of reconstituted HDL, 
composed of human apoAI and phosphatidylcholine, also decreased AAA 
formation in both AngII-infused hypercholesterolemic apoE-/- mice and calcium 
chloride administered normocholesterolemic C57BL/6 mice (124). Findings 
from this study implicate potential associations between apoAI and AAAs. 
To determine roles of specific lipoprotein fractions in development of AngII-
induced AAAs, we used multiple mouse strains with dietary and 
pharmacological manipulations that resulted in different forms and severity of 
hypercholesterolemia.  The occurrence of AngII-induced AAAs in these mice 
was contrasted to the formation of atherosclerosis, which has been strongly 
associated with plasma apoB-containing lipoprotein concentrations in mouse 
studies.  These studies demonstrated that development of AngII-induced AAAs 
was augmented by elevation of apoB-containing lipoproteins, but not by 
deficiency of apoAI, the major structural apolipoprotein of HDL.  However, 
unlike atherosclerosis, there was no simple concentration-dependent 
association of plasma apoB-containing lipoproteins with AngII-induced AAAs. 
2.2 Methods 
2.2.1 Mouse Housing Condition and Diets 
C57BL/6J, apoA-I -/-, LDL receptor -/-, and apoE -/- mice were purchased from 
The Jackson Laboratory (Stock # 0664, 2055, 2207, and 2052, respectively; 
Bar 
Harbor, ME, USA). Breeding pairs of apoA-I +/+ x LDL receptor -/- and apoA-I -
/- x LDL receptor -/- mice were developed by Dr. Sorci-Thomas. Mice were 
maintained in individually vented cages (maximally 5 mice/cage) on a light:dark 
cycle of 14:10 hours. The cage bedding was Teklad Sani-Chip bedding (Cat # 
7090A, Harlan Teklad, Madison, WI, USA). Mice were fed a normal rodent 
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laboratory diet (Diet # 2918, Harlan Teklad; Madison, WI, USA) and given 
drinking water from a reverse osmosis system ad libitum. During experiments, 
mice were either continuously fed the normal diet or a Western diet (Diet # 
TD.88137; Harlan Teklad) containing 21% (wt/wt, which equals 42% 
calories/calories) saturated fat extracted from milk, 48.5% (wt/wt) carbohydrate, 
17.3% (wt/wt) protein, and 0.2% (wt/wt) cholesterol (0.15% supplemented, and 
0.05% from the fat source) 1 week prior to and during 4 weeks of AngII 
infusion. Ezetimibe was provided by Merck & Company, Inc. Diets containing 
ezetimibe (50 mg/kg) were customized by Harlan Teklad. All procedures were 
performed with the approval of the University of Kentucky Institutional Animal 
Care and Use Committee. 
2.2.2 Osmotic Mini Pump Implantation and AngII Infusion 
AngII (1,000 ng/kg/min or 500 ng/kg/min; Cat# H-1706; Bachem; Torrance, CA, 
USA) was infused subcutaneously via Alzet osmotic mini pumps (Alzet Model # 
2004;Durect; Cupertino, CA, USA) as described previously. Only apoAI +/+ and 
-/- mice in an LDL receptor -/- background fed a Western diet were infused with 
AngII 500 ng/kg/min. Mice were sedated with isoflurane and pumps were 
implanted subcutaneously on the right flank of each mouse. Surgical staples 
were used to close the incision site and a topical anesthetic cream (LMX4; 
Ferndale Laboratories; Ferndale, MI) was applied immediately after surgery to 
relieve pain. 
2.2.3 Systolic Blood Pressure Measurements 
Systolic blood pressure was measured using a standardized protocol described 
Previously (105) on conscious mice for 3 consecutive days prior to (baseline) 
and during the last week of AngII infusion by a non-invasive tail-cuff system 
(Coda 8; Kent Scientific; Torrington, CT, USA). 
2.2.4 Measurement of Plasma Components 
Mice were anesthetized using ketamine/xylazine cocktail at termination. Blood 
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samples were harvested by right ventricular puncture with EDTA (final 
concentration: 1.8 mg/ml) and then centrifuged at 400 g x 20 minutes at 4 C̊ to 
prepare plasma. 
Plasma cholesterol concentrations were measured using an enzymatic kit (Cat 
# 439-17501; Wako Chemicals USA, Richmond, VA, USA). Plasma lipoprotein 
distributions were resolved by size exclusion gel chromatography followed by 
enzymatic measurement of cholesterol in each collected fraction, as described 
previously (104).  
Plasma renin concentrations were measured using a method described in our 
previous publication (234).  Briefly, plasma samples harvested with EDTA were 
incubated in an assay buffer (Na2HPO4 0.1 M; EDTA 0.02 M, maleate buffer pH 
6.5, phenylmethylsulfonyl fluoride 2 μl; total volume of 250 μl) with an excess of 
rat angiotensinogen at 37 ̊C for 30 minutes.  Rat angiotensinogen was obtained 
through partial purification of nephrectomized rat plasma.  Reactions were 
terminated by placing samples at 100 ̊C for 5 minutes.  AngI generated in each 
sample was quantified by radioimmunoassay using a commercially available kit 
(Cat # 1553; DiaSorin, Stillwater, MN, USA). 
2.2.5 Quantification of Aortic Pathologies 
At termination, after blood collection, the right atrium was cut open, and saline 
was perfused through the left ventricle to remove blood from the systemic 
circulation. Subsequently, aortas were dissected and placed in 10% neutrally 
buffered formalin overnight at room temperature. After fixation, periaortic 
adventitia was carefully removed. 
Necropsies were performed for mice that died during AngII infusion. Aortic 
rupture was defined as observation of blood clots in either the thoracic cavity 
(thoracic aortic rupture) or retroperitoneal cavity (abdominal aortic rupture). 
Maximal outer diameter of the suprarenal aorta was measured ex vivo as a 
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parameter for abdominal aortic aneurysm (AAA) quantification using Image-Pro 
software (Version 7; Media Cybernetics; Bethesda, MD, USA). Thoracic aortas 
were cut open and pinned for quantification of intimal area and atherosclerotic 
lesion area in a region including ascending, arch and 3 mm of descending aorta 
using an en face technique (107, 228). Atherosclerosis was compared between 
groups with percent lesion area (lesion area/intimal area x 100%). 
2.2.6 Statistical Analysis  
Data were analyzed using SigmaPlot version 12 (SYSTAT Software Inc., 
Chicago, IL, USA). Data are represented as means ± standard error of means 
(SEM). To compare two study groups of each experiment on a continuous 
variable, unpaired two-tailed Student’s t test was performed for normally 
distributed and equally variant values, and Mann-Whitney rank sum test were 
used for non-normally distributed variables. Systolic blood pressure was 
analyzed using two-way repeated measures ANOVA. P < 0.05 was considered 
statistically significant. 
2.3 Results 
2.3.1 Western Diet Had No Effects on AngII-induced AAA Formation in 
Male C57BL/6 Mice 
Prolonged feeding of a high fat diet (60% calories from saturated fat) augments 
AngII-induced AAAs in normocholesterolemic mice that have become obese 
(101). Therefore, in the initial experiment we determined whether Western diet 
(42% calories from milk fat) per se had effects on AngII-induced AAAs in wild-
type C57BL/6J mice.  Male C57BL/6J mice were fed either a normal or Western 
diet and infused with AngII (1,000 ng/kg/min) for 4 weeks.  Western diet feeding 
started 1 week prior to AngII infusion and was maintained during AngII infusion. 
There was no significant body weight gain difference between mice fed normal 
versus Western diet. Western diet feeding modestly increased plasma total 
cholesterol concentrations in C57BL/6 mice (Figure 2.1A). With no overt 
presence of apoB-containing lipoproteins, HDL was the predominant lipoprotein 
in these mice fed either diet as defined by size exclusion chromatography 
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(Figure 2.1B).  There were no differences of body weight or LDL/HDL ratio 
between C57BL/6 mice fed normal versus Western diet (Table 2.1 and 2.2). No 
discernable atherosclerotic lesions were detected in these mice.  One of 10 
mice (10%) from each group died of aortic rupture.  There were no significant 
differences in maximal outer diameter of suprarenal aortas between mice fed 
these two diets (Figure 2.1C). 
2.3.2 Deficiency of ApoAI Did Not Exacerbate AngII-induced AAA 
Formation 
HDL is the major lipoprotein fraction in plasma of male C57BL/6 mice (Figure 
2.1B), and apoAI is the predominant structural apolipoprotein of HDL. To 
determine whether low HDL augmented AngII-induced AAAs, we compared 
AngII-induced AAA formation between male apoAI+/+ and -/- mice in a 
C57BL/6 background fed the normal laboratory diet and infused with AngII 
(1,000 ng/kg/min) for 4 weeks. There were no differences of body weight 
between two apoAI+/+ and -/- mice (Table 2.1). Deficiency of ApoAI led to 
significant reductions of plasma cholesterol concentrations (Figure 2.2A) due to 
reductions of HDL-cholesterol concentrations (Figure 2.2B).  One of 10 mice 
(10%) from each group died of aortic rupture.  Deficiency of ApoAI did not 
augment AngII-induced AAAs in C57BL/6 background (Figure 2.2C).  
Effects of apoAI deficiency were also studied in male LDL receptor-/- mice. In 
the first experiment, mice were infused with 1,000 ng/kg/min of AngII and fed 
the normal laboratory diet.  Plasma total cholesterol or apoB-containing 
lipoprotein concentrations were not significantly different between the two 
apoAI genotypes (Figure 2.3A and 2.3B), whereas plasma HDL-cholesterol was 
barely detectable in mice with apoAI deficiency fed the normal laboratory diet 
(Figure 2.3B).  Atherosclerotic lesions were minimal and not significantly 
different between the two genotypes (Figure 2.3C).  Consistent with findings in 
C57BL/6 mice, apoAI deficiency in LDL receptor-/- mice had no effects on 
AngII-induced AAA formation (Figure 2.3D).  Since apoAI deficiency was 
hypothesized to enhance AngII-induced AAA formation, infusion rates of AngII 
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were selected to create a low incidence of AAAs in apoAI+/+ mice to enable 
demonstration of enhanced AAAs in apoAI-/- mice.  Subsequently, we 
compared AngII-induced AAAs using an infusion rate of 500 ng/kg/min between 
apoAI+/+ and -/- mice with LDL receptor-/- background that were fed the 
Western diet. As with normal diet, apoAI deficiency led to profound reductions 
of plasma cholesterol concentrations with barely detectable HDL with Western 
diet (Figure 2.4 A and 2.4B). Atherosclerotic lesions were modestly reduced in 
mice with apoA-I deficiency (Figure 2.4C).  In agreement with the other studies 
described above, apoAI deficiency in LDL receptor-/- mice fed the Western diet 
did not exacerbate AngII-induced AAA formation (Figure 2.4D).  One of 12 mice 
that were wild type for apoAI died of abdominal aortic rupture, whereas no 
apoAI-/- mice died of aortic rupture. 
2.3.3 Hypercholesterolemia Augmented AngII-induced AAA in Male LDL 
Receptor -/- Mice 
LDL receptor-/- mice fed normal laboratory diet are modestly hyper-
cholesterolemic with comparable cholesterol distributions between apoB-
containing lipoproteins and HDL.  Previous studies have reported high 
susceptibility to AngII-induced AAA in this mouse model fed Western diet to 
AngII-induced AAAs (114, 235). However, AngII-induced AAAs have not been 
reported in this mouse model fed normal laboratory diet.  To determine whether 
augmented hypercholesterolemia influenced AAA formation in LDL receptor-/- 
background, male mice of this genotype were fed either normal or Western diet 
and infused with AngII 1,000 ng/kg/min for 4 weeks.  Western diet feeding 
greatly increased plasma total cholesterol concentrations compared to mice fed 
normal laboratory diet (Figure 2.5A).  These increases were solely attributed to 
increased apoB-containing lipoproteins that included chylomicrons, chylomicron 
remnants, very low density lipoprotein (VLDL), and LDL (Figure 2.5B). Body 
weight was not significantly different between two groups (Table 2.1). LDL/HDL 
ratios were increased in male LDL receptor-/-mice fed Western diet, compared 
to those fed a normal laboratory diet (Table 2.2)  As expected, the greatly 
augmented hypercholesterolemia promoted by Western diet feeding profoundly 
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increased atherosclerotic lesions (Figure 2.5C).  Western diet also significantly 
increased AAA formation, as defined by maximal outer diameters of suprarenal 
aortas (Figure 2.5D).  No deaths due to aortic rupture occurred in these mice. 
Male sex has been demonstrated to enhance AngII-induced AAA formation in 
apoE-/- mice (74, 75, 77). To determine whether hypercholesterolemia has 
similar effects in both sexes, female LDL receptor-/- mice fed either normal or 
Western diet were infused with AngII 1,000 ng/kg/min for 4 weeks.  As with 
males, body weight was not significantly different between two groups (Table 
2.2). Western diet feeding profoundly increased plasma cholesterol 
concentrations due to increased apoB-containing lipoprotein cholesterol 
concentrations (Figure 2.6A and 2.6B). Consistent with data from male LDL 
receptor-/- mice, Western diet feeding augmented atherosclerotic lesions 
(Figure 2.6C).  Despite equivalent elevations in plasma cholesterol 
concentrations as male mice, Western diet feeding did not augment AngII-
induced AAAs in female LDL receptor-/- mice (Figure 2.6D).  No deaths due to 
aortic rupture occurred in female mice. 
2.3.4 Comparable AngII-induced AAA Formation in Male ApoE-/- Mice Fed 
Normal versus Western Diet  
Although there have been no direct comparisons, it is inferred from the 
literature that AngII-induced AAAs are equivalent between apoE-/- mice fed 
normal versus Western diet (57, 58). To compare directly, male apoE-/- mice 
were fed either normal or Western diet and infused with AngII 1,000 ng/kg/min. 
Body weight was not significantly different between two groups (Table 2.1). 
ApoE-/- mice fed a normal laboratory diet had plasma cholesterol 
concentrations of 347 ± 38 mg/dl, and Western diet feeding led to profound 
increases (1260 ± 121 mg/dl) due to increased apoB-containing lipoprotein 
cholesterol concentrations (Figure 2.7A and 2.7B).  In agreement with findings 
in LDL receptor-/- mice, Western diet feeding significantly increased 
atherosclerotic lesions (Figure 2.7C).  However, there was no difference in 
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AngII-induced AAAs (Figure 2.7D) or death due to aortic rupture (60% versus 
40%) between mice fed normal and Western diets. 
2.3.5 Reduction of Plasma ApoB-containing Lipoproteins Attenuated 
AngII-induced AAA Formation in Male ApoE -/- Mice Fed Normal Diet  
Results from LDL receptor-/- mice fed Western diet and apoE-/- mice fed either 
diet implicate that high concentrations of plasma apoB-containing lipoproteins 
contribute to augmentation of AngII-induced AAAs.  ApoE-/- mice are 
endogenously hypercholesterolemic even when fed the normal laboratory diet. 
Therefore, to determine whether reduced apoB-containing lipoprotein 
concentrations attenuate development of AngII-induced AAAs in male apoE-/- 
mice, we administered an intestinal cholesterol absorption inhibitor, ezetimibe, 
started one week prior to initiating AngII infusion (1,000 ng/kg/min). Body 
weight was not significantly different between two groups (Table 2.1). In male 
apoE-/- mice fed Western diet, plasma cholesterol concentrations were reduced 
compared to mice not administered the drug.  However, this concentration (546 
mg/dl) was still high, with a predominance of high plasma apoB-containing 
lipoproteins (Figure 2.8A and 2.8B).  This reduction was associated with 
attenuation of atherosclerosis (Figure 2.8C), whereas dilation of suprarenal 
aortas (Figure 2.8D) and death due to aortic rupture (control versus ezetimibe: 
30% versus 40%) were not significantly different.    
The same dose of ezetimibe decreased plasma cholesterol concentrations from 
451 ± 8 mg/dl to 204 ± 18 mg/dl in male apoE-/- mice fed a normal laboratory 
diet (Figure 2.9A) and infused with AngII (1,000 ng/kg/min).  This is similar to 
plasma cholesterol concentrations in LDL receptor-/- mice fed the same diet. 
Body weight was not significantly different between two groups (Table 2.1). 
This reduction was due to decreased plasma apoB-containing lipoproteins 
(Figure 2.9B). Atherosclerotic lesion sizes were minimal in both groups (Figure 
2.9C).  Aortic rupture rate was comparable between two groups (control versus 
ezetimibe: 30% versus 20%).  However, administration of ezetimibe decreased 
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AngII-induced AAA formation as determined by maximal outer diameters of 
suprarenal aortas (Figure 2.9D). 
43 
2.4 Discussion 
Aberrant metabolism of specific lipoprotein fractions, particularly LDL and HDL, 
is associated with atherosclerotic diseases and modulation of their plasma 
concentrations is a tenet of therapeutic strategies (236). Dysfunctional 
lipoprotein metabolism has also been implicated in human AAA formation, 
although associations have not been studied extensively (227). In this study, 
AngII-induced AAAs in multiple mouse models with different plasma lipoprotein 
distributions were used to determine whether facets of dyslipidemia directly 
associated with AAA formation.  We were unable to define any effect of 
reduced HDL-cholesterol concentrations, promoted by apoAI deficiency, on 
AngII-induced AAA formation in two mouse strains with dietary manipulations.  
However, our findings clearly demonstrated that hypercholesterolemia 
augmented the development of AngII-induced AAAs in mice.  Changes in large 
sized lipoprotein particles were associated with augmentation of AngII-induced 
AAAs.  The only feature in common for these lipoproteins was the presence of 
apoB.  However, unlike atherosclerosis in which plasma apoB-containing 
lipoprotein concentrations closely correlated with lesion size, AAAs were 
augmented with modestly hypercholesterolemic states, but not further 
enhanced with progressive increases in hypercholesterolemia. 
HDL-cholesterol has been associated with AAAs in humans in a limited number 
of observational studies (104, 105, 107, 109, 237, 238). Recent experimental 
evidence consistent with this association demonstrated that administration of 
exogenous native or reconstituted HDL reduced AngII-induced AAAs (124). We 
performed the converse study in which plasma HDL concentrations were 
reduced markedly by genetic deficiency of apoAI.  ApoAI deficiency did not 
augment AngII-induced AAAs in C57BL/6 mice fed a normal laboratory diet.  
This lack of effect was also demonstrated in LDL receptor-/- mice fed either 
normal or Western diet.  Therefore, depletion of endogenous apoAI had no 
discernable effect on AngII-induced AAAs.  The mechanisms by which 
exogenously delivered apoAI and its endogenous reduction have differential 
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effects on AngII-induced AAAs are unclear.  A similar contrast of HDL 
supplementation versus genetic deficiency has been observed in 
atherosclerosis studies, with overexpression of apoAI reducing atherosclerosis 
(239, 240), but apoAI deficiency did not augment atherosclerosis (241, 242). 
ApoAI deficiency was reported to be associated with (243) or have no 
correlations with (244) coronary heart disease in humans.  Although a few 
studies suggested that low plasma apoAI concentrations were associated with 
AAAs in patients (107, 238, 245), no studies reported whether apoAI deficiency 
was associated with the development of AAAs. 
Chronic AngII infusion into normocholesterolemic mice induces AAAs at a rate 
that has ranged from 5% to 40% (49, 101, 113-115). In contrast, the incidence 
of AngII-induced AAAs in hypercholesterolemic mice has routinely been over 
70% (79, 81, 113, 114). Hypercholesterolemic mice in these previous studies 
have included LDL receptor-/- mice fed Western diet or apoE-/- mice fed either 
normal or Western diet (57, 58). Ezetimibe lowered plasma cholesterol 
concentrations in apoE -/- mice fed normal laboratory diet to approximately 200 
mg/dl.  This reduction in plasma apoB-containing lipoproteins significantly 
attenuated abdominal aortic dilation.  Ezetimibe also reduced the extent of 
hypercholesterolemia in apoE-/- mice fed Western diet.  While this reduction 
decreased atherosclerosis, it did not attenuate aortic dilation.  This result 
demonstrated that reduced AAAs in apoE-/- mice administered ezetimibe and 
fed normal laboratory diet was not attributed to a direct effect of the drug.  
These findings from male LDL receptor-/- or apoE-/- mice fed normal versus 
Western diet, coupled with results using ezetimibe, demonstrate that 
substantial reductions in apoB-containing lipoproteins are required to attenuate 
AngII-induced AAAs in mice.  Consistent with our findings, increased 
concentrations of plasma LDL, a major class of apoB-containing lipoproteins, 
have been associated with AAAs in humans (105, 227, 246, 247). 
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ApoB-containing lipoproteins encompass a heterogeneous mix of lipoprotein 
particles with a range of lipid and apolipoprotein compositions.  One study 
reported that LDL incubation with cultured human smooth muscle cells 
increased AT1 receptor mRNA and inferred this was the cause of increased 
response to AngII in hypercholesterolemic patients (248).However, although 
whole body depletion of AT1a receptors ablates AngII-induced increases of 
AAAs in hypercholesterolemic mice (131), deletion of AT1a receptors 
specifically in smooth muscle cells had no effects on AngII-induced AAAs (134, 
249). One mechanism of AngII-induced AAAs is that AngII promotes leukocyte 
infiltration both systemically and locally into the aortic wall (64, 65, 81). 
Hypercholesterolemia also promotes leukocyte infiltration in arteries (250) or 
facilitates AngII-induced leukocyte mobilization into the arterial wall (136). In 
our future studies, it will be important to explore mechanisms by which 
hypercholesterolemia and AngII have synergistic effects on leukocyte infiltration 
to promote AAA formation. 
We have demonstrated previously that AngII-induced AAAs in apoE-/- mice 
have a strong sexual dimorphism with males being much more susceptible to 
aortic expansion (78). This dimorphism is ablated by orchidectomy (74, 75, 77). 
The current study demonstrated this dimorphism also exists in LDL receptor-/- 
mice and that Western diet feeding increased plasma cholesterol 
concentrations to a similar magnitude in both sexes and led to equivalent 
atherosclerotic development.  However, there was no difference on AngII-
induced AAA formation in female mice fed the Western versus normal diet.  
Mechanisms of male gender preference in hypercholesterolemic mice remain to 
be defined. 
In summary, this study demonstrated that increased plasma concentrations of 
apoB-containing lipoproteins are associated with augmentation of AngII-
induced AAAs in a male-gender specific manner.  Most interestingly, unlike 
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atherosclerosis, AngII-induced AAAs were not further augmented with 
progressive increases of plasma apoB-containing lipoprotein concentrations. 
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Figure 2.1 Western diet did not augment AngII-induced AAA formation in male C57BL/6 mice.  (A) 
Plasma cholesterol concentrations.  Histobars are means and error bars represent SEM.  * 
denotes P=0.03 by Mann-Whitney Rank Sum Test.  N=9 per group.  (B)  Plasma lipoprotein 
distributions were resolved by size exclusion chromatography. Circles and error bars are means ± 
SEM.  N=6-8 per group. CM: chylomicrons, VLDL: very low-density lipoprotein, LDL: low-density 
lipoprotein, and HDL: high-density lipoprotein.  (C)  Maximal outer diameters of suprarenal aortas. 
Triangles are values from individual mice.  Circles represent means and error bars are SEM.  
P=0.6 by Mann-Whitney Rank Sum Test. N=9 per group. 
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Figure 2.2 Deficiency of ApoAI in male C57BL/6 mice did not exacerbate AngII-induced AAA 
formation.  (A)  Plasma cholesterol concentrations. Histobars are means and error bars represent 
SEM. * denotes P<0.001 by Student’s t test.  N=9 per group.  (B)  Plasma lipoprotein distributions 
were resolved by size exclusion chromatography.  Circles and error bars are means ± SEM. N=4 
per group.  CM: chylomicrons, VLDL: very low-density lipoprotein, LDL: low-density lipoprotein, 
and HDL: high-density lipoprotein.  (C)  Maximal outer diameters of suprarenal aortas. Triangles 
are values from individual mice.  Circles represent means and error bars represent SEM.  P=0.2 
by Mann-Whitney Rank Sum Test. N=9 per group.   
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Figure 2.3 Deficiency of ApoAI had no effect on AngII-induced AAAs in male LDL receptor -/- mice 
fed a normal laboratory diet.  (A)  Plasma cholesterol concentrations.  Histobars are means and 
error bars represent SEM. N=5-6 per group.  (B)  Plasma lipoprotein distributions resolved by size 
exclusion chromatography.  Circles and error bars are means ± SEM. N=3 per group. (C) Percent 
atherosclerotic lesion area in the aortic arch regions. (D) Maximal outer diameters of suprarenal 
aortas.  Triangles are values from individual mice, and circles represent means and error bars 
represent SEM (C and D). N=7 per group. 
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Figure 2.4 Deficiency of ApoAI did not exacerbate AngII-induced AAAs in male LDL receptor -/- 
mice fed Western diet.  (A)  Plasma cholesterol concentrations.  Histobars are means and error 
bars represent SEM. N=11-13 per group.  * denotes P< 0.001 by Mann-Whitney Rank Sum Test.  
(B)  Plasma lipoprotein distributions resolved by size exclusion chromatography. Circles and error 
bars are means ± SEM. N=4-5 per group.  (C)  Percent atherosclerotic lesion area in the aortic 
arch regions.  N=10-13 per group * denotes P= 0.03 by Student’s t test.  (D)  Maximal outer 
diameters of suprarenal aortas. N=11-13 per group.  * denotes P=0.01 by Mann-Whitney Rank 
Sum Test.  Triangles are values from individual mice, and circles represent means and error bars 
represent SEM (C and D). 
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Figure 2.5 Hypercholesterolemia increased AngII-induced AAA formation in male LDL receptor -/- 
mice.  (A)  Plasma cholesterol concentrations. Histobars are means and error bars represent SEM. 
* denotes P<0.001 by Mann-Whitney Rank Sum Test.  N=10 per group.  (B)  Plasma lipoprotein
distributions were resolved by size exclusion chromatography.  Circles and error bars are means ± 
SEM.  N=10 per group.  CM: chylomicrons, VLDL: very low-density lipoprotein, LDL: low-density 
lipoprotein, and HDL: high-density lipoprotein.  (C)  Atherosclerosis in the aortic arch region.  
Triangles are values from individual mice.  Circles represent means and error bars represent SEM. 
* denotes P<0.001 by Mann-Whitney Rank Sum Test. N=10 per group.  (D)  Maximal outer
diameters of suprarenal aortas.  Triangles are values from individual mice.  Circles represent 
means and error bars represent SEM.  * denotes P=0.002 by Mann-Whitney Rank Sum Test.  
N=10 per group. 
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Figure 2.6 Hypercholesterolemia did not increase AngII-induced AAA formation in female LDL 
receptor -/- mice.  (A)  Plasma cholesterol concentrations. Histobars are means and error bars 
represent SEM.  N=10 per group. * denotes P<0.001 by Student’s t test.  (B)  Plasma lipoprotein 
distributions resolved by size exclusion chromatography.  Circles and error bars are means ± 
SEM. N=5-7 per group.  (C)  Percent atherosclerotic lesion area  in the aortic arch regions.  N=10 
per group.  * denotes P<0.001 by Mann-Whitney Rank Sum Test.  (D)  Maximal outer diameters of 
suprarenal aortas.  N=10 per group. 
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Figure 2.7  Modest and severe hypercholesterolemia had equivalent effects on AngII-induced AAA 
formation in male ApoE-/- mice.  (A)  Plasma cholesterol concentrations.  Histobars are means and 
error bars represent SEM. * denotes P=0.01 by Mann-Whitney Rank Sum Test.  N=4-6 per group.  
(B)  Plasma lipoprotein distributions were resolved by size exclusion chromatography. Circles and 
error bars are means ± SEM. N=4-5 per group. CM: chylomicrons, VLDL: very low-density 
lipoprotein, LDL: low-density lipoprotein, and HDL: high-density lipoprotein.  (C)  Atherosclerosis in 
aortic arch region.  Triangles are values from individual mice.  Circles represent means and error 
bars represent SEM.  * denotes P=0.02 by Mann-Whitney Rank Sum Test. N=4-6 per group.  (D)  
Maximal outer diameters of suprarenal aorta.  Triangles are values from individual mice.  Circles 
represent means and error bars represent SEM for each group.  P=0.7 by Student’s t test.  N=4-6 
per group. 
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Figure 2.8 Administration of ezetimibe reduced atherosclerosis, but not  AngII-induced AAA 
formation in male ApoE-/- mice fed Western diet.  (A)  Plasma cholesterol concentrations.  
Histobars are means and error bars represent SEM for each group. * P=0.001 by Mann-Whitney 
Rank Sum Test. N=6-7 per group.  (B)  Plasma lipoprotein distributions were resolved by size 
exclusion chromatography.  Circles and error bars are means ± SEM. N=4-7 per group. CM: 
chylomicrons, VLDL: very low-density lipoprotein, LDL: low-density lipoprotein, and HDL: high-
density lipoprotein.  (C)  Atherosclerosis in the aortic arch region.  Triangles are values from 
individual mice. Circles represent means and error bars represent SEM.  N=6-8 per group.  (D)  
Maximal outer diameters of suprarenal aortas.  Triangles are values from individual mice.  Circles 
represent means and error bars represent SEM. *P=0.965 by Student’s t test.  N=6-8 per group. 
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Figure 2.9 Administration of ezetimibe reduced AngII-induced AAA formation in male ApoE-/- mice 
fed normal laboratory diet.  (A)  Plasma cholesterol concentrations.  Histobars are means and 
error bars represent SEM.  * denotes P<0.001 by Student’s t test.  N=6-8 per group.  (B)  Plasma 
lipoprotein distributions were resolved by size exclusion chromatography.  Circles and error bars 
are means ± SEM. N=4-7 per group. CM: chylomicrons, VLDL: very low-density lipoprotein, LDL: 
low-density lipoprotein, and HDL: high-density lipoprotein.  (C)  Atherosclerosis in aortic arch 
regions.  Triangles are values from individual mice.  Circles represent means and error bars 
represent SEM.  P=0.256 by Student’s t test. N=6-8 per group.  (D)  Maximal outer diameters of 
suprarenal aortas.  Triangles are values from individual mice.  Circles represent means and error 
bars represent SEM.  P=0.009 by Student’s t test.  N=6-8 per group. 
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     Table 2.1 Characteristics of normal diet and Western diet fed mice 
Strain Diet Gender
Body Weight Systolic 
BP 
(mmHg) 
Renin 
(ng/ml/30 
min) Initial Final 
C57BL/7 
Normal Diet Male 22.9 ± 0.3 26.5 ± 0.3  182 ± 8   2.71 ±0.19 
Western Diet Male 23.3 ± 0.3 25.7 ± 0.4 187 ± 5 2.52 ± 0.07 
ApoA-I +/+ Normal Diet Male 25.6 ± 0.6 26.1 ± 0.6 189 ± 5 1.08 ± 0.02 
ApoA-I -/- Normal Diet Male 23.5 ± 0.8 24.5  ± 0.6 182 ± 5 1.14 ± 0.14 
LDLr -/- 
Normal Diet Male 20.8 ± 0.5 24.6 ± 0.6 162 ± 5 2.15 ± 0.1 
Western Diet Male 21.4  ± 0.4 26.9 ± 0.5 175 ± 7 1.7 ± 0.05 
LDLr -/- 
Normal Diet Female 18.3 ± 0.4 19.6 ± 0.2 176 ± 7 1.15 ± 0.04 
Western Diet Female 17.9 ± 0.4 19.8 ± 0.4 173 ± 8 1.22 ± 0.07 
ApoE -/- 
Normal Diet Male 24.1 ± 0.3 29.0 ± 1.2 184 ± 8 2.14 ± 0.06 
Western Diet Male 24.5 ± 0.6 28.7 ± 1.5 140 ± 8 2.13 ± 0.40 
ApoE -/- 
Normal Diet Male 25.7 ± 0.5 28.9 ± 0.5 171 ± 3 1.3 ± 0.07 
Normal Diet + EZ Male 24.3 ± 0.5 27.1 ± 0.7 185 ± 7 1.48 ± 0.11 
Western Diet Male 24.9 ± 0.6 27.2 ± 0.8  167 ± 11 1.07 ± 0.05 
Western Diet + EZ Male 24.5 ± 0.4 26.9 ± 0.4 187 ± 7 1.09 ± 0.04 
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Table 2.2 Ratio of LDL/HDL in male mice infused with AngII for 28 days 
Mouse Strain Normal diet Western diet P value 
C57BL/6 0.15 ± 0.02 0.12 ± 0.02 0.3 
LDL receptor -/- 1.38 ± 0.21 2.98 ± 0.35 0.004 
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Chapter Three: ApoB-containing Lipoproteins Promote the Progression of 
Established AAAs in AngII Infused Mice 
3.1 Introduction 
Abdominal aortic aneurysm (AAA) is a devastating disease that exhibits gradual 
and permanent lumen expansion that is typically presenting in the infrarenal 
region.  Population-based screening studies demonstrate that AAA is prevalent 
among aged population especially in males.  As an AAA progresses, it remains 
asymptomatic until rupture occurs leading to sudden and fatal hemorrhage. 
Since the AAA size is the major predictor of rupture, attempts should be made 
to slow the progressive expansion of AAA. To date, there is no proven medical 
therapy that can prevent either dilation or rupture of AAA.  
Experimental mouse models have demonstrated that hypercholesterolemia 
enhances development of AAA and there is accumulating evidence that it is 
also a contributor to human AAA pathologies (105, 227, 246, 251). Chronic 
infusion of angiotensin II (AngII) induces AAA formation in 
normocholesterolemic mice (49, 110, 113-115, 233) with a much lower 
incidence than in hypercholesterolemic mice (56-58). Human observational 
studies demonstrated a positive correlation of plasma LDL-C concentrations 
and the presence of human AAA (105, 227, 246, 251).  
Although numerous pharmacological targets have been explored to address 
mechanisms contributing to the initiation of AAAs, few studies have 
investigated pharmacological approaches that would inhibit the progression of 
established AAA.  A recent study demonstrated prolonged infusion of AngII into 
hypercholesterolemic mice promoted further lumen expansion (65) which 
implicated a potential role of hypercholesterolemia in the progression of 
established AAA induced by AngII infusion. In line with this finding, a meta-
analysis including more than 9,000 patients from 7 high-quality observational 
studies demonstrated a statistically significant benefit of statin therapy for 
growth rate in patients with small AAAs. Although the mechanism underlying 
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lipid-lowering treatment is undefined, statins are commonly administered to 
AAA patients to reduce aortic expansion (110, 112).  
To determine the role for hypercholesterolemia in progression of established 
AAA in mice with prolonged infusion of AngII, we performed a diet switch of 
Western to normal diet that led to a quick and profound reduction in plasma 
cholesterol concentration within one week. Consistent with previous study, 
lumen expansion progressed in mice maintained on Western diet; while no 
further expansion was detected in mice that were switched to normal diet.  
3.2 Methods 
3.2.1 Mouse Housing Condition and Diets 
Male LDL receptors -/- mice (8 weeks of age) were purchased from The 
Jackson Laboratory (Stock # 2207; Bar Harbor, ME, USA). Mice were 
maintained in individually vented cages (maximally 5 mice/cage) on a light:dark 
cycle of 14:10 hours.  The cage bedding was Teklad Sani-Chip bedding (Cat # 
7090A, Harlan Teklad, Madison, WI, USA).  Mice were fed a normal rodent 
laboratory diet (Diet # 2918, Harlan Teklad; Madison, WI, USA) and given 
drinking water from a reverse osmosis system ad libitum. To induce AAAs, all 
mice were infused with AngII (1,000 ng/kg/min) for 4 weeks and fed a Western 
diet supplemented with saturated fat extracted from milk (21 %, wt/wt) and 
cholesterol (0.15 % wt/wt supplemented, 0.05 % wt/wt from the fat source; Diet 
# TD.88137; Harlan Teklad).  On day 27 of AngII infusion, lumen diameter of 
suprarenal aortas was measured using noninvasive high frequency ultrasound 
(Vevo 2100, Visualsonics, Toronto, Ontario, Canada). AAAs were defined as 
50% increase of maximal lumen diameter compared to baseline in the 
suprarenal aortas. Based on lumen diameter, mice exhibiting AAAs were 
evenly stratified into two groups, that were either continuously fed western diet 
or switched to a normal diet. All mice were infused with AngII for an additional 8 
weeks.  
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3.2.2 Osmotic Mini Pump Implantation and AngII infusion 
AngII (1,000 ng/kg/min; Cat# H-1706; Bachem; Torrance, CA, USA) was 
infused subcutaneously via Alzet osmotic mini pumps (Alzet Model # 2006; 
Durect; Cupertino, CA, USA) for 42 days. Pumps were pre-incubated in saline 
at 37 ̊C for 60 hours. All mice were implanted with new mini pumps (Alzet 
Model # 2006) at day 43 to permit continuous delivery of AngII for another 6 
weeks. Mice were sedated with isoflurane and pumps were implanted 
subcutaneously on the right flank of each mouse.  Surgical staples were used 
to close the incision site and a topical anesthetic cream (LMX4; Ferndale 
Laboratories; Ferndale, MI) was applied immediately after surgery to relieve 
pain.  
3.2.3 Systolic Blood Pressure Measurements 
Systolic blood pressure was measured using a standardized protocol described 
previously on conscious mice for 3 consecutive days by a non-invasive tail-cuff 
system (Coda 8; Kent Scientific; Torrington, CT, USA). Systolic blood pressure 
was measured one week before mini pump implantation (baseline) and 
repeated on week 9 during AngII infusion. 
3.2.4 Ultrasound Measurement and 3-dimensional Imaging 
Reconstruction 
Lumen diameter of suprarenal aortas was measured using the Vevo 2100 
ultrasound imaging system (Visualsonics, Toronto, Ontario, Canada). Mice 
were anesthetized with isoflurane and restrained in a supine position. Short-
axis scans (100 frames of cine loops) were acquired from the level of the left 
renal artery moving cephalically to the suprarenal region. The maximal lumen 
diameter of the suprarenal region was measured on collected images during 
the aortic dilation phase. To reconstruct three-dimensional (3D) images, mice 
were whole-body fixed by 10% naturally buffered formalin perfusion in vivo to 
preserve aortic structure. Aortas were subsequently dissected and placed in 
formalin overnight at room temperature. Periaortic adventitia was then carefully 
removed. Cleaned aortas were submerged in saline solution. Ex vivo 3D mode 
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was performed on abdominal aortas to obtain sequential 2D cross-section 
images. Vevo software was used to assemble the serial scans into 3D images 
and for quantification of total and lumen volumes of AAA. Vascular volumes of 
AAA were calculated by subtracting lumen volumes from total volumes. To 
compare volumes between two groups, we reconstructed 15 mm length of AAA 
segments with the most dilated lumen at the center to minimize variations 
caused by heterogeneity of AAA pathologies. 
3.2.5 Measurement of Plasma Components 
Detail was described in Chapter 2 (2.2.4). 
3.2.6 Quantification of Aortic pathologies 
Detaill was described in Chapter 2 (2.2.5). 
3.2.7 Histological Staining and Immunohistology 
We chose whole-body perfusion fixed mice with suprarenal aortic diameters 
that were similar to the mean for each group for histological analysis of AAAs. 4 
mm above right renal artery of suprarenal aortas were carefully excised and 
placed in OCT. Serially cross-sections were performed (10 μm thick/section, 
series of 10 slides with 9 sections/slide) from the proximal to the distal as 
described previously (64, 65). H&E and Movat’s pentachrome stainings were 
used to determine morphological characteristics and elastin fibers. Oil Red-O 
staining was used to examine the neutral lipid and triglyceride deposition. 
Immunostaining was performed to identify macrophages and smooth muscle 
cells as described previously (252).  The following antibodies were used: α-
actin for smooth muscle cells (Cat # ab5694; Abcam; Cambridge, MA) and 
CD68 for macrophages (Cat#MCA1957GA, Serotec; Raleigh, NC); Biotin 
labeled secondary antibodies (Cat # BA-4001 and BA-6000; Vector 
Laboratories; Burlingame, CA); horseradish peroxidase ABC kits (Peroxidase 
Elite Standard; Cat # PK-6100; Vector Laboratories; Burlingame, CA) and 3-
amino-9-ethylcarbazole for chromogen (ImmPACTTM; Cat # SK-4205; Vector 
Laboratories; Burlingame, CA).  Non-immune primary antibodies, secondary 
only, and no primary or secondary antibody slides were run as negative 
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controls to confirm specificity of primary and secondary antibodies, and ablation 
of endogenous tissue peroxidase, respectively. 
3.2.8 Primary Aortic Smooth Muscle Cell Culture 
Primary aortic smooth muscle cells isolated from C57BL/6 (Cell Biologics; Cat # 
C57-6080; Chicago, IL)were grown in a 5% CO2 atmosphere at 37 °C in DMEM 
supplemented with 1% nonessential amino acids, 20% FBS and 1% penicillin 
and streptomycin. Cells were grown to confluence and serum starved for 24 
hours before use.  
3.2.9 Isolation of Plasma Lipoproteins  
To prepare LDL and VLDL, blood from western diet fed LDL receptor -/- mice 
(N=10) was collected by right ventricular puncture with syringes containing 
EDTA (final concentration: 1.8 mg/ml) and pooled, then centrifuged at 400 g x 
20 minutes at 4 ̊C to separate plasma. LDL and VLDL were isolated from 
plasma samples by sequential ultracentrifugation. Briefly, plasma samples were 
carefully loaded into 3.5 ml Quick-Seal centrifuge tubes partially filled with 
saline (1.006 g/ml) and centrifuged for 3 hours at 100 K rpm (TLA 100.3 rotor, 
Beckman instrument) to float up the VLDL. Then the density of remaining 
plasma was adjusted to 1.063 g/ml with solid KBr and carefully loaded under a 
layer of 1.061 g/ml KBr solution. Ultracentrifugation was performed at 100 K 
rpm for 3 hours. Isolated LDL and VLDL were placed into dialysis bags 
(Molecular weight cutoff: 12-14 kD; Spectra; Cat # 132676) and placed in 1 liter 
of cold EDTA saline solution in the cold room. Dialysis fluid was changed every 
1 hour for two times. 
3.2.10 RNA Isolation and Real-time PCR  
Total RNA in primary aortic smooth muscle cells was extracted with a RNeasy 
Mini Kit (Qiagen), and then reversely transcribed with an iScript™ cDNA 
Synthesis Kit (Cat#170- 8891; Bio-Rad, Hercules, CA). Real time PCR was 
performed to quantify mRNA abundance using a SsoFast™ EvaGreen® 
Supermix kit (Cat# 172-5203; Bio-Rad) on a Bio-Rad CFX96 cycler. Data were 
analyzed using ∆∆Ct method, normalized to β-actin abundance. Primers used 
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for AT1a Receptor and β-actin  in real-time PCR were 5’-
ACTCACAGCAACCCTCCAAG, 5’ ATCACCACCAAGCTGTTTCC and 5’-
GCCTTCCTTCTTGGGTATGG, 5’-GCACTGTGTTGGCATAGAGG, 
respectively. 
3.2. 11 Statistical Analysis 
Data were analyzed using SigmaPlot version 12 (SYSTAT Software Inc., 
Chicago, IL, USA).  Data are represented as means ± standard error of means 
(SEM). To compare three study groups in each experiment on a continuous 
variable, one way ANOVA was performed for normally distributed and equally 
variant values, and Kruskal-Wallis One Way Analysis rank sum test were used 
for non-normally distributed variables.  Systolic blood pressure was analyzed 
using two-way repeated measures ANOVA. P < 0.05 was considered 
statistically significant. 
3.3 Results 
3.3.1 Characteristics of Study Mice 
To induce AAA, eighty male LDL receptor -/- mice were fed Western diet one 
week prior to and four weeks during AngII infusion (1,000 ng/kg/min). During 
the 28-day infusion, 9 mice died of aortic rupture. On day 27, the abdominal 
aortas of remaining mice were scanned by ultrasound to determine presence of 
AAA. Mice with AAAs were randomly stratified and divided into two groups 
based on their abdominal aortic lumen diameter. After stratification, mice either 
remained on the Western diet (n=17) or were switched to a normal laboratory 
diet (n=17). AngII infusion was continued for an additional 8 weeks. The 
experimental design for this study is illustrated in Figure 3.1. Body weight was 
not significantly different between the mice either remained on Western diet or 
switched to a normal diet (Table 3.1). During the prolonged interval, 1 mouse 
died of aortic rupture in the group remaining on Western diet and 2 mice died of 
aortic rupture in the diet reversal group, respectively.  
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3.3.2 Western Diet Withdrawal Led to Rapid Reductions of Plasma Total 
Cholesterol Concentrations  
Mice fed Western diet were significantly hypercholesterolemic compared with 
the baseline (1469 ± 59 mg/dl versus 250 ± 9 mg/dl). In order to determine the 
effect of reduction of plasma cholesterol concentrations on established AAA 
progression, hypercholesterolemia was reversed by switching Western diet to a 
normal laboratory diet after stratification. Strikingly, diet reversal resulted in 
significantly reduced plasma cholesterol concentrations within one week (535 ± 
31 mg/dl versus 1621 ± 62 mg/dl) which were maintained for the remaining 
interval (two-week diet switch: 382 ± 22 mg/dl versus 1845 ± 69 mg/dl; at 
termination: 1661 ± 54 mg/dl versus 312 ± 12 mg/dl; Figure 3.2A). The 
lipoprotein profile was determined by size exclusion chromatography at study 
termination. The reduction of plasma cholesterol concentrations were solely 
attributed to decreased apoB-containing lipoproteins that included 
chylomicrons, chylomicron remnants, very low density lipoprotein (VLDL), and 
LDL (Figure3.2B). 
3.3.3 Decreased ApoB-containing Lipoproteins Attenuated Lumen 
Expansion of AngII-induced AAA 
Lumen diameter of the suprarenal region was monitored by ultrasound during 
the study. Consistent with our previous report (65, 66), in mice maintained on 
Western diet, lumen diameter increased progressively with protracted AngII 
infusion. In contrast, further expansion of abdominal aortic lumen diameter was 
not detected in mice switched to a normal diet. This significant attenuation 
measured with ultrasound was confirmed at study termination by ex vivo 
measurement of suprarenal aortas (Figure 3.3A and B).  
3.3.4 Reductions of ApoB-containing Lipoproteins Contributed to 
Reduced Aortic Remodeling 
The profound reduction of apoB-containing lipoproteins resulted in decreased 
lumen and external diameter in diet reversal mice. To better understand and 
provide more insight into the disease, we performed three-dimensional (3D) 
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AAA reconstruction imaging. We reconstructed 15 mm length of AAA with the 
most dilated lumen at the center to minimize the variations caused by the 
heterogeneity of AAA pathologies (Figure 3.4A). We quantified the total aortic 
volumes, lumen volumes and vascular volumes which were calculated by 
subtracting the lumen volumes from the total aortic volumes. The diet reversal 
mice with profound reductions of apoB-containing lipoproteins exhibited lower 
total aortic volumes, lumen volumes and vascular volumes (Figure 3.4B).  
3.3.5 Reduction of ApoB-containing Lipoproteins Attenuated Medial 
Thickening and Inflammation 
Pathologies of AngII-induced AAA exhibit high heterogeneity and complex 
features even along the length of a single aneurysm (64, 65). To determine 
whether profound reductions of apoB-containing lipoproteins influenced AAA 
pathological characteristics, entire AAA segments were serially cross-sectioned 
and examined at 100 μm interval throughout the aneurysmal tissue to account 
for the considerable heterogeneity along the length of the aorta. Prolonged 
AngII infusion in mice maintained on Western diet resulted in significant lumen 
expansion associated with profound medial thickening around the AAA 
segment. Adjacent to the dilated region, adventitia was also thickened. In 
contrast, in the diet reversal mice, the adventitia and medial thickening were 
significantly attenuated and had less macrophage accumulation in the media 
(Figure 3.5).  
3.3.6 Effects of ApoB-containing Lipoproteins on AT1a Receptor in Aortic 
Smooth Muscle cells 
Elevated concentrations of native LDL (253) have been reported to upregulate 
gene expression of the AT1 receptors and its functional response to the 
stimulation of AngII both in vitro and in vivo. (253, 254) A human study also 
demonstrated hypercholesterolemia induced AT1 receptor overexpression and 
enhanced biological effects of AngII in men (255). Therefore, we examined 
whether apoB-containing lipoproteins promoted expansion of AAA through the 
interaction between AngII and the upregulated AT1a receptor. Since LDL and 
VLDL are the major components of apoB-containing lipoproteins and the 
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inflammatory response was the most prominent in the media, we investigated 
the effects of LDL and VLDL on AT1a receptor gene expression in cultured 
primary aortic vascular smooth muscle cells (VSMCs). Cells were grown to 
confluency and serum was removed from the culture medium 24 hours before 
initiation of experimental treatment. Reports indicate that AT1 receptor mRNA 
significantly increases 12 hours after exposure to LDL and this increase is 
sustained for up to 24 hours (253). To determine LDL-induced enhancement of 
AT1a receptor expression, cells were incubated for 24 hours with 0, 25, 50, 
100, and 200 ug/ml LDL or VLDL. However, neither LDL nor VLDL significantly 
altered AT1a receptor expression in the mouse primary aortic smooth muscle 
cells (Figure 3.6A and B). 
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3.4 Discussion 
Dysregulated lipoprotein fractions, especially apoB-containing lipoproteins are 
associated with development of human AAA. A few studies also implicated 
statins, the lipid-lowering drugs, were beneficial of reducing AAA growth rate. 
The rupture of AAA is a devastating event that occurs during the progression of 
this disease with the aneurysm size is the most robust predictor. The risk of 
rupture increases exponentially with elevated aneurysm diameter. In this study, 
we determined the influence of apoB-containing lipoproteins in mice with 
established AAA. To achieve this, AAA was induced by 28 days AngII infusion 
in western diet fed mice. Then we evenly stratified the mice with AAA into two 
groups based on their lumen diameter. They were either maintained on 
Western diet or switched to a normal laboratory diet for an additional 8 weeks 
of AngII infusion. Of note, significantly decreased plasma cholesterol 
concentrations were noted within one week after diet switching and they were 
maintained for the remaining study interval. Significant attenuation of 
established AAA progression in diet switched group was detected by ultrasound 
during the study and this observation was confirmed by ex vivo measurement 
of suprarenal region at termination. This profound attenuation was associated 
with less vascular remodeling and inflammatory accumulation.  
Hypercholesterolemia reversal has been achieved in several mouse models. 
Microsurgical transplantation of arterial segments containing atherosclerotic 
plaques from hypercholesterolemic mice into normocholesterolemic 
counterparts has been used to investigate the plaque regression (264-266). 
Hsiao and colleagues developed “Reversa mice” in which using Cre/loxP 
techniques, the conditional alleles of microsomal triglyceride transfer protein 
(Mttp) were switched off in the liver. They bred LDL receptor -/- mice that were 
homozygous for an apoB-100-only allele with mice that were homozygous for a 
conditional Mttp allele and Mxl-Cre transgene. Offspring were bred to produce 
mice that were homozygous for all 4 alleles (LDL receptor -/- apoB100/100 Mttpfl/fl
Mxl-Cre+/+) To inactivate Mttp, Cre expression was induced by intraperitoneal 
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injections of polyinosinic-polycytidylic ribonucleic acid (pI-pC) every other day 
for a total of 4 injections (267). Another study conducted by Maganto-Garcia et 
al also reversed just by simply switched the diet fed LDL receptor -/- mice. They 
designed a study in which mice were fed a cholesterol diet for 4 weeks and 
then a cholesterol-free diet for an addition 4 weeks to reverse the 
hypercholesterolemia. The diet switch significantly decreased plasma 
cholesterol concentration to the level of mice on control diet. Considering the 
practical limitation of time and money-consuming for the complex mouse 
breeding and technical issues for the transplantation surgery, in our study, the 
reduction of apoB-containing lipoprotein was achieved by diet switch. We found 
statistically significant reduction of plasma cholesterol concentrations as early 
as day 3 of diet switch. So our diet switching protocol might be a potentially 
easier and less costly procedure design for investigating reversal of 
hypercholesterolemia. 
Nickenig and colleagues demonstrated that elevated native LDL upregulates 
the AT1a receptor gene expression and its biological functions. In this regard, 
we performed the similar experiments-we isolated the mice LDL and VLDL and 
cultured them with primary SMCs. However, we were unable to identify 
upregulation of AT1a receptors in mouse primary aortic smooth muscle cells.  
It is known that the expression pattern of AT1a receptors along the entire aorta 
is different and the abdominal region is more susceptible to AAA formation. 
Therefore, the isolation of smooth muscle cells from abdominal aorta might be 
more relevant. We previously demonstrated although the whole body AT1a 
receptor deficiency attenuated AngII-induced AAA, the deletion of AT1a 
receptors on single type did not prevent aneurysm formation. This implicating 
orchestrated contributions of multiple cell types in the interaction of AngII and 
AT1a receptor to promote AAAs. Therefore, multiple cell type co-incubations 
should be optimal to investigate regulation of AT1a receptors and interactions 
and cross-talking among different vascular cell types in a hypercholesterolemic 
environment.  
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Figure 3.1 Overall experimental design. Male LDL receptors -/- mice fed western diet were 
infused with AngII for 28 days to induce AAAs. On day 27, the abdominal aortas of all mice 
were scanned by ultrasound to determine the presence of AAAs. Mice with AAAs were 
randomly stratified and divided into two groups which remained on western diet or were 
switched to a normal diet. AngII infusion was continued for another 8 weeks for all mice. 
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Figure 3.2 Diet reversal significantly reduced plasma cholesterol concentrations in mice 
with established AAA. (A) Plasma cholesterol concentrations. Circles and error bars are 
means ± SEM. * denotes P< 0.001 by Two-way repeated measurement ANOVA. N=9-16 
per group. (B) Plasma lipoprotein distributions were resolved by size exclusion 
chromatography at study termination. Circles and error bars are means ± SEM. N=11 per 
group. CM: chylomicrons, VLDL: very low-density lipoprotein, LDL: low-density lipoprotein, 
and HDL: high-density lipoprotein. 
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Figure 3.3 Profound reduction of apoB-containing lipoproteins by diet switch attenuated 
further lumen expansion in mice with established AAA. (A) Suprarenal aortic lumen 
diameter measured by ultrasound at various time points (Left). Ultrasound images of 
representative aortas in each group measured at study termination illustrated less 
expansion in diet switch group (Right). Circles and error bars are means ± SEM. * denotes 
P< 0.001 by Two-way repeated measurement ANOVA. N=15-16 per group. (B) Maximal 
outer diameters of suprarenal aortas. Triangles are values from individual mice. Circles and 
error bars are means ± SEM. * denotes < 0.001 by Mann-Whitney Rank Sum Test. (C) 
Aortas from mice in each group.  
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Figure 3.4 Profound reduction of apoB-containing lipoproteins by diet switch attenuated 
aortic remodeling. (A) Three-dimensional (3D) images of a representative AAA from a 
mouse in each group. (B) Volumes of suprarenal aortas were measured on 3D 
reconstructed images of ex vivo AAAs. Triangles are values from individual mice. Circles 
and error bars are means ± SEM. * denotes P< 0.05 Student’s t test. 
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Figure 3.5 Representative serial cross-sections from abdominal aortas were
immunostained for SMCs (α-actin) and macrophages (CD68). Red color indicates positive
staining.  
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Figure 3.6 AT1a receptor mRNA did not increase in primary aortic smooth muscle cell
cultured with various LDL (A) and VLDL (B) concentrations. Histobars are means and error
bars represent SEM. N=2 per group. 
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Table 3. 1 Characteristics of mice maintained on Western diet or switched to 
normal diet with continuous AngII infusion  
Group  N  Body weight  Systolic BP (mmHg) 
Renin 
(ng/ml/30
min) Initial  Stratification  Final 
Western diet  16  22.7 ± 0.3  26.4 ± 0.3  27.4 ± 0.7  165 ± 7  1.3 ± 0.1 
Diet switch  15  23.1 ± 0.4  27.0 ± 0.5  28.1 ± 0.6  158 ± 7  1.5 ± 0.3 
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Chapter Four: General Discussion and Future Directions 
4.1 Section One 
Aberrant lipoprotein metabolism, particularly LDL and HDL fractions, is 
associated with many cardiovascular diseases. Dysfunctional lipoprotein 
metabolism has also been implicated in human AAA formation, although 
associations have not been studied extensively. In Chapter 2, we used multiple 
mouse strains with dietary and pharmacological manipulations to create 
different forms and severities of dyslipidemia to determine whether specific 
lipoprotein fractions directly contributed to AngII-induced AAA formation.  We 
were unable to identify any effects of reduced HDL-cholesterol concentrations, 
promoted by apoAI deficiency, on AngII-induced AAA formation in two mouse 
strains with dietary manipulations.  However, our findings clearly demonstrated 
that hypercholesterolemia, especially the large sized lipoprotein particles, 
augmented the development of AngII-induced AAAs in mice.  The only feature 
in common for these lipoproteins was the presence of apoB.  However, unlike 
atherosclerosis in which plasma apoB-containing lipoprotein concentrations 
closely correlated with lesion size, AAAs were augmented under modestly 
hypercholesterolemic states, but were not further enhanced with progressive 
increases in hypercholesterolemia. 
4.1.1 Dysregulation of Lipoproteins in Human AAA 
There is accumulating evidence of dysregulated lipoproteins, particularly HDL 
and LDL fractions, being critical contributors to the prevalence and severity of 
human AAA. To address this issue, the concentrations of blood lipids and 
apolipoproteins in subjects were measures in the reported studies. The first 
study published by Norrgard and colleagues (104), reported an association 
between human HDL-C and AAA. They observed the concentration of HDL-C 
in serum was lower in patients than in the healthy controls. However, a 
subsequent study conducted by Louwrens et al (106) reported AAA patients 
had a higher HDL-C concentration compared with the control. In contrast with 
this latter study, several studies subsequently showed that the presence of 
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human AAA was negatively associated with the level of both HDL-C or apoAI, 
the predominant structural apolipoprotein of HDL (14, 105, 107, 109, 227, 237, 
238, 246, 256). In addition, a study by Femke et al found a negative association 
between serum HDL-C with human aneurysm size (257). A later study 
demonstrated serum apoAI is inversely associated with AAA size and thrombus 
volume in patients. Of note, this study also demonstrated HDL-C negatively 
correlated with growth rate of AAA and the need for later repair (245).  
Besides abnormal HDL-C, the contribution of dysregulated LDL-C to human 
AAA has also drawn attention for many decades. It was observed that AAA 
patients had higher (VLDL+LDL)-cholesterol or total cholesterol concentrations 
than healthy controls (104, 227, 258). However, several studies identified LDL-
C as the only independent predictor of the presence of human AAA (105, 247, 
251). Of note, although the above studies implicate the alteration of plasma 
lipids might contribute to the AAA, one single study identified the size of LDL 
was independently associated with the presence of human AAA (109). In 
contrast to these findings, a study conducted by Golledge (237) reported the 
concentration of LDL-C was not directly associated with the presence of human 
AAA, which was confirmed by a subsequent meta-analysis (246). Regardless of 
this undefined association, statins, the lipid-lowering drugs, are commonly used 
for AAA patients to reduced aortic expansion. In line with this, a recent meta-
analysis published by a Japanese group (259) demonstrated a statistically 
significant benefit of stain therapy for growth rate in patients with small AAA. 
Overall, the non-consistent findings and limited number of studies impede the 
understanding of the impact of dysregulated lipoprotein fractions on human 
AAA. The interpretation of the results from those studies could be greatly 
confounded by the coexistence of other cardiovascular diseases and the use of 
multiple medications. Given this undefined association and complex situation in 
humans, using our in vivo system with genetic and pharmacological 
manipulations in multiple mouse models, we overcame these issues and 
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provided direct evidence for an association between dysregulated lipoproteins 
and the development of AAA. On the basis of our data, generated from multiple 
mouse models to manipulate apoAI- or apoB-containing lipoproteins, we 
conclud that apoB-containing lipoproteins augmented the development of 
AngII-induced AAA. However, unlike the linear correlation between 
atherosclerotic size and plasma apoB-containing lipoproteins, AAA was 
exacerbated by modestly increased apoB-containing lipoproteins but not 
enhanced with further increase of hypercholesterolemia. This result clearly 
demonstrated the divergent mechanisms underlying the pathological processes 
of atherosclerosis and AAA which require further elucidation. One interesting 
question remains whether this “threshold” effect of AAA development observed 
in our mouse studies also applies to observational human studies.  One 
indication reported by Forsdahl et al is the increased risk of AAA was only 
observed in subjects with the highest reading (highest quartile) of total 
cholesterol; however, no statistically significant association was observed in 
other quartiles (227). If this “threshold” effect in mouse also applies to human 
AAA, the conflicting results might be explained as different criteria of plasma 
cholesterol concentrations in different studies. If the level of plasma cholesterol 
concentrations in the study is below or above the threshold, no direct 
correlation would be observed. So further investigation is needed to elucidate 
the association between apoB-containing lipoproteins and human AAA. 
4.1.2 Role of HDL in AngII-induced AAA 
There is a large body of evidence of abnormal HDL-C being a major contributor 
of numerous cardiovascular diseases. HDL plays a pivotal role in reverse 
cholesterol transport (RCT), a pathway by which cholesterol is transported from 
peripheral tissues to the liver where it is secreted through biliary excretion. RCT 
is a key pathway in maintaining cholesterol balance. In addition to its role in 
promoting the RCT pathway, HDL possesses anti-oxidative, anti-inflammatory, 
anti-thrombotic, anti-apoptosis and anti-platelet activity properties (260). This 
broad spectrum of effects for HDL and the similarity of risk factors between 
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AAA and other cardiovascular diseases provide the basis for potential 
therapeutic benefits of HDL in the treatment of AAA. In line with this, one study 
reported by Torsney et al demonstrated that exogenous administration of 
pooled native HDL or reconstituted HDL reduced AngII-induced AAA in both 
AngII and CaCl2 mouse models (124). The reconstituted HDL, CSL111, is 
composed of human apoAI and soybean phosphatidylcholine thereby 
resembling native HDL. It has been demonstrated that these nascent particles 
will be rapidly remodeled with endogenous lipoproteins into the mature HDL 
particles within one hour after intravenous injection (261). Another recent study 
conducted by Burillo et al reported reduction of AAA development by 
administration of ApoAI mimetic peptide D4F (245). In their study, an apoAI 
mimetic peptide was intraperitoneally injected into AngII infused apoE -/- mice 
during progression of the disease. The development of AAA was monitored by 
high frequency ultrasound with a VEVO770 system. They observed a 
decreased lumen expansion in the D4F treated group compared with control 
counterparts.  
To better understand why C57BL/6 mice with HDL fractions as the predominant 
lipoproteins were protected from AngII-induced AAA formation, we performed 
the converse study in which plasma HDL concentrations were reduced 
markedly by genetic deficiency of apoAI. ApoAI deficiency significantly reduced 
HDL-C while it did not augment AngII-induced AAAs in C57BL/6 mice fed a 
normal laboratory diet. Effects of apoAI deficiency were also studied in male 
LDL receptor-/- mice.  Since apoAI deficiency was hypothesized to enhance 
AngII-induced AAA formation, infusion rates of AngII were selected to create a 
low incidence of AAAs to demonstrate the enhancement of AAAs in apoAI-/- 
mice. We compared AngII-induced AAAs using an infusion rate of 1000 
ng/kg/min between apoAI +/+ and -/- mice fed normal diet and a rate of 500 
ng/kg/min between apoAI +/+ and -/- mice fed western diet. Consistent with 
finding in C57BL/6 mice, apoAI deficiency in LDL receptor-/- mice did not 
exacerbate AngII-induced AAA formation. 
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The mechanisms by which exogenously delivered ApoAI and its endogenous 
reduction have differential effects on AngII-induced AAAs are unclear. A critical 
question is whether HDL or its major apolipoprotein ApoAI involved during the 
formation of AngII-induced AAA? It is noteworthy that HDL is more complex 
than originally proposed. In addition to the major apolipoproteins in HDL, it has 
been reported that there are over 40 different proteins and various potent 
bioactive signaling molecules, such as paraoxonase and vitamin E, associated 
with HDL particles (262). These proteins and molecules have a large spectrum 
of functions involving inflammation, proteolysis and oxidation pathways. For 
example, paraoxonase is an enzyme carried and transported by HDL particles 
that could neutralize oxidized lipids. It is known that overexpression of this 
enzyme decreased atherosclerosis while the deficiency exacerbated the 
atherosclerosis. So this implicates many of these beneficial roles of HDL were 
likely to be indirect consequences of the interaction between HDL on cells and 
possibly related to its ability to transport some of these proteins and molecules. 
Of note, although administration of reconstituted HDL prevented the formation 
of AngII-induced AAA and attenuated the expansion of AAA in CaCl2 model, the 
elevation of HDL in this study was only minimal which might suggest that the 
protective role of HDL could be mediated by those transported proteins. 
ApoAI consists of 243 amino acids and its secondary structure contains 10 
amphipathic α-helices that are critical for the interaction with lipids. Studies on 
HDL/apoAI-based-therapy provide convincing evidence on their protective role 
in atherosclerosis. However, a major practical limitation of these therapies is 
the large quantity of HDL that is needed for treatment. In this regard, 
considerable investigations have been made to develop apoAI mimetic 
peptides containing the α-helix that mimics functional properties of apoAI. The 
D4F peptide is the most widely studied apolipoprotein mimetic peptide. In the 
Burillo et al study, although HDL-C and apoAI concentrations were not reported 
after the administration of D4F, another study has demonstrated that 
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administration of D4F did not affect plasma or HDL cholesterol levels (263). If 
the HDL or apoAI are critical in the development of AAA, it is interesting to 
answer why administration of D4F profoundly attenuated the AngII-induced 
AAA formation without overt effects on HDL-C level? It has been noticed that 
administration of D4F increased pre-β HDL which was enriched in paraoxonase 
activity and led to increased HDL anti-oxidant capacity and decreased 
atherosclerosis (263).  
Taken together, these two reports (124) did not contradict with our findings. 
Instead, these results suggest that the investigation of HDL function as a carrier 
for other critical proteins and signaling molecules other than the actual 
concentration of HDL or apoAI might be more interesting. 
4.2 Section Two 
Since clinical intervention would be initiated following detection of an 
established AAA, in Chapter 3, we determined the influence of apoB-containing 
lipoproteins in mice with established AAA. To achieve this, AAA was induced by 
28 days AngII infusion in western diet fed mice. Then we evenly stratified the 
mice with AAA into two groups based on their lumen diameter. They were 
either maintained on Western diet or switched to a normal laboratory diet for an 
additional 8 weeks of AngII infusion. Significantly decreased plasma cholesterol 
concentrations were noted within one week after diet switching and they were 
maintained for the remaining study interval. Significant attenuation of 
established AAA progression in diet switched group was detected by ultrasound 
during the study and this observation was confirmed by ex vivo measurement 
of suprarenal region at termination. This profound attenuation was associated 
with less vascular remodeling and inflammatory accumulation. We concluded 
Chapter 3 by demonstrating apoB-containing lipoproteins contributed to the 
progression of established AAA and provided evidence on the potential 
therapeutic benefit of a lipid-lowering treatment during the progression of 
established AAA. 
82 
4.2.1 Plasma Cholesterol Concentration Reversal 
The hypercholesterolemic mouse models have become a critical platform for 
atherosclerosis research. Studies with these mice have explored the impacts of 
genes and pharmacological manipulations on the development of 
atherosclerosis and other related cardiovascular diseases thereby facilitating 
mechanistic understanding of interventions during disease progression. The 
reversal of hypercholesterolemia is also important to investigate during plaque 
regression, delayed progression, and remodeling and stabilization of 
atherosclerotic lesion.  
The microsurgical transplantation of arterial segments has been used in 
numerous rodent models. Syngeneic transplantation of descending thoracic 
aortas containing advanced atherosclerosis from hypercholesterolemic mice 
into normocholesterolemic counterparts have been used to determine the 
development of advanced atherosclerosis. In one report, thoracic aortic 
segments containing preexisting atherosclerotic lesions from aged apoE -/- 
mice were transplanted into the infrarenal abdominal aortas of wild-type 
normolipidemic recipients. The marked regression of atherosclerotic lesion was 
observed (264). In another study, thoracic aortas from apoE -/- mice were 
transplanted in apoE -/- mice that expressed human ApoAI. The elevated 
human HDL in the recipients halted progression of established atherosclerosis 
(265).  Subsequently, elegant work by Chereshnev and colleagues provided a 
new mouse model using heterotopic aortic arch transplantation with more 
severe lesion compared with segments of descending aortas and demonstrated 
this was a useful alternative model for the investigation (266). 
In developing a hypercholesterolemic mouse model in which plasma 
cholesterol concentrations could be reversed with a simple intervention, Hsiao 
and colleagues developed “Reversa mice” in which using Cre/loxP techniques, 
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the conditional alleles of microsomal triglyceride transfer protein (Mttp) were 
switched off in the liver. They bred LDL receptor -/- mice that were homozygous 
for an apoB-100-only allele with mice that were homozygous for a conditional 
Mttp allele and Mxl-Cre transgene. Offspring were bred to produce mice that 
were homozygous for all 4 alleles (LDL receptor -/- apoB100/100 Mttpfl/fl Mxl-
Cre+/+) and named “Reversa mice”. To inactivate Mttp, Cre expression was 
induced by intraperitoneal injections of polyinosinic-polycytidylic ribonucleic 
acid (pI-pC) every other day for a total of 4 injections. Hypercholesterolemia 
could be reversed in these mice without intervention of diet or lipid-lowering 
medication (267).  
Another study conducted by Maganto-Garcia et al also reversed 
hypercholesterolemia in order to investigate regulatory T cells function (268). In 
their study, they just simply switched the diet fed LDL receptor -/- mice. They 
designed a study in which mice were fed a cholesterol diet for 4 weeks and 
then a cholesterol-free diet for an addition  4 weeks to reverse the 
hypercholesterolemia. The diet switch significantly decreased plasma 
cholesterol concentration to the level of mice on control diet. 
Consistent with the Maganto-Garcia study, investigating the role of apoB-
containing lipoproteins on established AAA, we also reversed 
hypercholesterolemia by simply switching the Western diet to normal laboratory 
diet. We found within one week of diet switching, plasma cholesterol 
concentration was profoundly reduced and maintained for the remaining 
interval. There is no doubt that reversal of hypercholesterolemia by gene switch 
off and surgery are useful mouse models. However, the practical limitations are 
the time and money-consuming for the complex mouse breeding and technical 
issues for the transplantation surgery. So our diet switching protocol might be a 
potentially easier and less costly procedure design for investigating reversal of 
hypercholesterolemia. 
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4.2.2 Effects of LDL on AT1a Receptor Regulation 
AngII is the main bioactive peptide of the RAS system. Its principle functions 
are involved in the modulation of blood pressure, maintaining water and sodium 
homeostasis, neuronal function and other neurohumoral systems (269, 270). 
Although initial investigation with AngII focused on its role in the pathogenesis 
of hypertension, emerging evidence has indicated that AngII is a critical effector 
in development of atherosclerosis, myocardial infarction, vascular remodeling 
and heart failure (271-274). Effects of AngII are mediated through the 
interaction with its receptors. The main AngII receptors are G protein-couple 
receptors designated as angiotensin receptor type 1 (AT1) and angiotensin 
receptor type 2 (AT2). There are two subtypes of the AT1 receptors (AT1a and 
AT1b) in rodents.  
There is evidence that the renin angiotensin system contributes to experimental 
AAAs.  Inhibition of angiotensin-converting enzyme (ACE) or AT1 receptors 
reduces elastase-induced AAAs (50-53) or decellularise aortic xenograft-
induced AAAs (54) in rats and multiple mouse models (55). Besides this 
evidence that implicates the endogenous activation of AngII in the 
pathogenesis of AAA, more direct evidence from animal models is AAA 
formation and rupture in mice infused with AngII. Moreover, the whole body 
deletion of AT1a receptor diminishes AngII-induced AAA (131). In the AngII-
induced AAA mouse model, chronic AngII infusion into normocholesterolemic 
mice induces AAAs has ranged from 5% to 40% (49, 101, 113-115). In 
contrast, the incidence of AngII-induced AAAs in hypercholesterolemic mice 
has routinely been over 70% (81, 101, 113-115). Although this enhancement of 
AngII-induced AAA formation by hypercholesterolemia has been observed, the 
underlying mechanism is still poorly defined.  
Studies by Nickenig and colleagues demonstrated that elevated native LDL 
upregulates the AT1a receptor gene expression and its biological functions in 
both in vitro and in vivo. They also observed overexpression of AT1 receptor 
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and enhanced biological effects in hypercholesterolemic men when stimulated 
by AngII infusion. The elevated AT1a receptor by hypercholesterolemia might 
be a potential mechanism to enhance AAA formation in response to AngII 
stimulation. So we performed similar experiments using LDL and VLDL isolated 
from hypercholesterolemic mice and cultured with mouse primary aortic smooth 
muscle cells. However, we were unable to detect upregulation of AT1a 
receptors in primary aortic smooth muscle cells stimulated by co-culture with 
LDL.  
It is worth noting that in the Nickenig study, smooth muscle cells were isolated 
from rat thoracic aorta and co-cultured with LDL isolated from human 
normolipidemic subjects. This method raises several questions that remain to 
be elucidated. Firstly, the expression pattern of AT1a receptors along the entire 
aorta is different and the region is more susceptible to AAA formation. 
Therefore, the isolation of smooth muscle cells from thoracic aorta might not be 
relevant. Secondly, it has been reported that LDL receptors from different 
animal species have different affinities and binding patterns with human apoB-
100, the major apolipoprotein recognized by LDL receptors (275). In Nickenig’s 
study, to investigate whether LDL receptors from different animal species 
recognizes the binding domain on human apoB-100, the interaction of LDL from 
healthy controls and familial binding defective apoB-100 (FDB) with cultured 
cells were examined. They found rat cells failed to distinguish between normal 
and FDB LDL and the binding affinity was 4-8 times lower than the human LDL 
receptor. The use of antibody Mb47 which is capable of blocking the binding of 
human LDL to human cells failed to inhibit the binding of human LDL to rat 
cells. These findings indicate that rat LDL receptors recognize human apoB 
different from the human receptor binding domain. The lack of effects we 
observed is possibly due to the distinct recognition pattern and different affinity 
between the interactions of human LDL to rat cells and mouse LDL to mouse 
cells. Besides, as mentioned previously, there have been consistent 
demonstrations that AT1 receptors antagonism reduces AngII-induced AAAs 
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which is attributed to interactions between AngII and AT1a receptors in mice 
because whole body deficiency of AT1a receptors ablates development of 
AngII-induced AAAs (131). However, although bone-marrow transplantation 
study indicated the role of AT1a receptor on resident cell of aortic wall are 
important,  using cell-specific deficient mice that had AT1a receptor depletion 
on leukocytes, endothelial cells, or smooth muscle cells did not define a single 
cell type that played a critical role in AngII-induced AAA development (131, 
134), implicating orchestrated contributions of multiple cell types in the 
interaction of AngII and AT1a receptor to promote AAAs. So the elevation of 
AT1 receptor driven by hypercholesterolemia in single cell type might not 
account for the exacerbation of AAA in response to AngII infusion. Therefore, in 
the future, multiple cell type co-incubations should be optimized to investigate 
regulation of AT1a receptors and interactions and cross-talking among different 
vascular cell types in a hypercholesterolemic environment.  
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